

Subject Index

a

- Abacavir 59, 82
- ABCA1 58
- ABCB1 54, 58
- Abciximab 21, 462, 1086, 1117, 1153
 - half-life in plasma 1167
- Abscisic acid, responsive element 980
- Absorption enhancer 1464
 - efficacy 1465
- N-Acetylglucosamine (GlcNAc) 679, 764, 849, 938
- N-Acetylglucosaminyl transferase 924
- N-Acetylmannosamine 1047
- N-Acetylmuramic acid 938
- N-Acetylneuramic acid 811, 1047
- N-Acetylneuraminic acid 772
- Acetylphosphate 1075
- Acetylcysteine
 - in drug delivery 1375
- Acinar formation assay 643
- Acinetobacter calcoaceticus* 706
- Acquired immuno deficiency syndrome, *see* AIDS
- Acromegaly 15
- Actilyse 461
- Actimmune 17, 467
- Actinorhodin 1807
 - structure 1814
- Activacin 461
- Activase 11, 461, 726
- Activase-rtPA 746
- Activated clotting time 1012
- Activated partial thromboplastin time (aPTT) 198
- Activated protein C 457
- Activator protein-1 236
- Actrapid 13, 470
- Acute lymphoblastic leukemia, *see* ALL
- Acute lymphocytic leukemia, *see* ALL
- Acute lymphoid leukemia, *see* ALL
- Acute myelogenous leukemia (AML) 502
 - radioimmunotherapy of 505
 - antibody treatment for 1121
- Ad5FGF-4 (Adenovirus 5 fibroblast growth factor-4)
 - analytical assay 161
 - analytical techniques for 164
 - clinical study 175
 - dose-response 174
 - genome structure 157
 - production 158
 - toxicology study 174
- Ad5FGF-4 (Adenovirus 5 fibroblast growth factor-4) vector
 - isolation of 156
 - production 156
- Ad5LacZ 172
- Adagen 475, 1399, 1401, 1411
- Adalimumab 22, 455, 1086, 1118, 1150, 1156, 1163
- Adeno-associated viral vector (AAV) 317
- Adenosine deaminase (ADA) 429
 - deficiency 1401
- Adenovirus plasmid 156
- Adenovirus serotype 5 (Ad5) 155
- Adjuvants 1423
 - for human vaccination 1425
 - mode of action 1424
 - ADMET (absorption, distribution, metabolism, excretion and toxicity) 1604, 1773
 - assessment 1604, 1628
 - basic principles 1786
 - models 1786
 - prediction system 1785
 - prediction tools 1796
 - profiling 1785

- properties 1775
- value of prediction 1798
- Adenosine triphosphate (ATP)
 - regeneration system 1074
- ADR (adverse drug reactions) 76
- Adult respiratory distress syndrome 1009
- Advaferon 467
- Advate 421, 459
- Adverse drug reaction 51
- Aequorea victoria* 1628
- AERx-dornase alfa 475
- Affinity chromatography
 - characterization of antibodies by 797
- Aflatoxin B1
 - CYP3A4 activated 1586
- AFP 482
- Agalsidase alpha 475
- Agalsidase beta 475
- Agarose 1380
- AGENT (angiogenetic GENE therapy) trial 175
 - safety 177
- AGENT 2 trial 176
 - safety 177
- Age-related macular degeneration 1280
- Agrobacterium tumefaciens* 903, 950
- AIDS (acquired immuno deficiency syndrome) 14
 - gene therapy 549
 - vaccine 1164
- Airway hyper responsiveness 234
- Akanthamoeba castellanii* 685
- Aktraphane 13
- Alamar blue dye metabolism 168
- Albuterol 59
- Aldurazyme 24, 475
- Alefacept 455
- Alemtuzumab 22, 455, 479, 1086, 1156
- Alfaferone 467
- Alfatronol 17, 468, 480
- Alferon LDO 467
- Alferon N 467
- Alglucerase 475
- Alkaline phosphatase 712
 - secreted 731
- ALL (acute lymphoid leukemia) 76, 202
 - murine model 203
- Alosetron 52
- Alpha-1 464
- Alpha-1 antitrypsin 463
 - from transgenic system 858
- Alpha-defensin 383
- Alphaferon 467–468, 480
- Alpha-fetoprotein 862
- Alpha-glucosidase 861
- Alpha-iduronidase 862
- AlphaNine SD 459
- Alphaparin 457
- Alpha-synuclein 329
- Altemol 467
- Alteplase 11, 461
- Alternating tangential filtration 1087
- Alzheimer disease (AD) 77, 1781
 - targeting 1286
 - pathways and targets for 625
 - epidemiology 326
- Amantadin 330
- AMAXA system 632
- Ambirix 19
- Ames false negatives 1625
- Ames false positives 1625
- Ames II 1527, 1633
- Ames test 1632
- Amevive 454–455, 1119
- Amiloride 1525
- Amino acid depletion
 - with glutaDON 537
- Aminoacyl-tRNA synthetase 1068
- Amino-3,8-dimethylimidazoquinoxaline 1634
- Amino-hydroxybenzoic acid 1823
- (2-Amino)isobutyric acid 413
- Aminolevulinic acids 1617
- (3-Aminomethyl)benzenesulfonylglycine 407–408
- Amino-3-methyl-imidazoquinoline 1634
- Aminopeptidase 1379
- 2-O-Aminopropyl oligoribonucleotide 261
- Amiodarone
 - clearance of 1594
 - CYP2C9 inhibitor 1590
- Amitriptyline
 - CYP3A4 activated 1586
- Ammonium tartrate 922
- Amoxibeta T1000 1352
- Amoxicillin 1352
- Amphotericin B 1370
- Ampicillin 610
 - resistant plasmids 1024
- Amyloid precursor protein (APP) 1782
 - processing scheme of 1783
- Amyloidosis 1286
- Anact C 454, 457
- ANAFP (a novel antifungal peptide) 483
- Anakinra 17, 464, 1118
- Analytical assay validation
 - regulations 1650
- Analytical methods

- in quality control 1557
- *in vivo* 1572
- specifications for drug substances and products 1561
- validation 1567
- Analytical protein A chromatography (APAC)
 - characterization of antibodies by 797
- Angelman syndrome (AS) 219
- Anger position network 1221
- Angioblasts
 - for angiogenesis 319
- Angiogenesis 1235
 - markers of 1281
 - non-tumor 1280
 - related disease 1278
- Angioedema, hereditary 859
- Angiogenetic switch 1279
- Angiogenic GENE therapy, *see* AGENT
- Angiomax 461
- Angiostatin 381
- Angiotensin-converting enzyme (ACE) 78, 317
- Angiox 461
- Animal models
 - selection 1658
- Animal rule 1662
- Animal, transgenic 29
 - biopharmaceuticals from 833, 995
- Anion-exchange HPLC 164
- Anistreolase 461
- Annexin 5 detection assay 644
- Annexin A1 1281
- Annexin V 1262
 - for SPECT studies 1263
- ANP, *see* atrial natriuretic peptide
- Antegren 1122
- Anthracycline 139
- Anthrax 1489
 - toxine 1166
- Antibiotic resistance gene 299
- Antibody 454
 - against infectious disease 1175
 - anti-neutrophil cytoplasmic 1195
 - anti nuclear 1190
 - binding haptens, peptides or proteins 1154
 - binding site 1163
 - bispecific 1174
 - categories 1150
 - chimeric 7, 1109, 1153
 - class determination 1107
 - combining site 1190
 - complexes of 1155
 - different fragments and formats 1274
 - epitope 1190
 - epitope/paratope interaction 1108
 - fully human 1111, 1113, 1157
 - half-lives of therapeutic 1166
 - humanized 1153
 - immunogenic 1150
 - in disease targeting 1273
 - isotope conjugates 1174
 - libraries 1157
 - linking of phenotype and genotype in selection systems 1161
 - marker for autoimmune disease 1189
 - murine 1156
 - naked 1169
 - on the market 1151
 - pharmacological characteristics of 1114
 - protective function of 1166
 - polyclonal 1109
 - radiotracer 1258
 - screening technologies 1160
 - single chain 1115
 - single domain 1115
 - synthetic 1176
- Antibody-antigen interaction 1190
- Antibody-dependent cellular cytotoxicity 733, 1274
- Antibody-directed enzyme prodrug therapy (ADEPT) 1277
- Antibody fragments 1113
 - manufacture in microbial systems 1088
 - pharmacokinetics of 1116
- Antibody library technology 1163
- Antibody response 1199, 1500
- Antibody technology 1147
- Antibody, therapeutic
 - productivity advantages 1726
- Anticoagulants 454
- Antide structure 1408
- Antiepileptic drugs 58
- Antigen-nanoparticle conjugate 1310
- Antigen-presenting cell 191, 360
- Antihemolytic factor VIII, *see* fVIII
- Antihemophilia agents 454
- Antinuclear autoantibodies, mononuclear 1371
- Antiperinuclear factor 1192
- Antisense RNA
 - for gene silencing 633
 - plasmid-borne 671
- Antisense technology 31
- Antithrombic agents 460
- Antithrombin (AT) 29, 995
 - anti-inflammatory activity 1009
 - hereditary deficiency 997, 1014
 - human 1001

- recombinant production of 998
- serpin 996
- vector construction 999
- Antithrombin III 458, 996
 - human 855
- Antithrombin transgene 999
- Anti-thymocyteglobulin 456
- Antitrypsin 463–464, 858
- Anti-tumor agent 474
- Antiviral agents
 - RNA-based 570
- Anril 464, 1117
- AP 486
- AP-1 233
- Apcitide 1283
- APEX 84
- Apidaecins 486
- Apidra 13, 469
- Aplysia kurodai* 482
- Apolipoprotein E (APOE)
 - locus 78
 - satin system 78
- Apoptosis 644
 - delaying 819
 - imaging 1238, 1262, 1284
- Aprepitant 1538
- AproliZean 903
 - Apronexin NP 854
- Aprotinin 904, 1470, 1472
 - from transgenic system 854
 - variants 1027
- Aptamers 635
- Arabidopsis thaliana* 869, 921, 950, 973
- Aralast 463
- Aralia elata* 482
- Aranesp 8, 472
- Arcitumomab 21
- Ardeparin sodium 458
- Area under the curve (AUC) 438
- Argatroban 413
- Argonaute protein family 222
- Argoproteins 245
- Arixtra 457
- ARMS 84
- Aroclor 1254, 1626
- ARPE-19 168
- Array-on technology 88
- Arterial re-stenosis 313
- Arthrobacter globiformis* 977
- Arthrobacter panescens* 977
- Artificial neural network 1789
 - for CNS activity prediction 1794
 - topology of three-layer 1790
- Ascorbate peroxidase 977
 - ROS scavenger 979
- Asialoglycoprotein 716, 1512
- Asialoorosomucoid 1512
- Asparaginase, PEGylated 543
- Aspergillus giganteus* 482
- Aspergillus terreus* 1804
- Astemizole 52
- Atenativ 458, 1006
- Atherosclerosis 313
 - targeting 1281
- Atomoxetine 57, 61, 64
 - label recommendation 56
- Atorvastatin 58
- Atrial natriuretic peptide (ANP) 290
- Atrioventricular block 298
- Atriplex gmelini* 974
- ATryn 29, 855, 995
 - clinical studies 1011
- Auerbach plexus 327
- Auger electron emitter 500
 - targeted radiotherapy with antibodies 524
- Auger electron radiotherapy
 - antitumor effects 519
 - gene-targeted 525
 - In-DTPA-D-Phe-octreotide 519
- Auristatin derivatives
 - cytotoxic 1172
- Autoantibody
 - antinuclear, mononuclear 1371
 - pathogenic 1188
 - responses 1187
- Autoantibody-autoantigen complexes
 - characterization of 1199
- Autographa californica*
 - nuclear polyhedrosis virus 1046
- Autoimmune disease 1187
- Autoimmune encephalomyelitis (EAE) 1200
- Autologous stem cell 500
- Auxotrophic marker 766
- Available chemical directory (ACD) 1790
- Avakine 456
- Avastin 143, 454–455, 479, 1121, 1169
- Average internal stability profile 250
- Avidin from transgenic systems 852
- Aviptadil 1742
 - dosage 1748
 - effects 1748
 - in PAH 1743
 - increase in CRE binding 1746
 - pharmacology 1744
 - release 1748
 - secretion enhancement 1748

- Avonex 17, 467, 1404
 5-Azacytidine 320
 5-Aza-2-deoxycytidine 294
- b**
- Baby hamster kidney cell line (BHK) 762
 BACE (beta-amyloid converting enzyme) 1773
 – complex 1784
 – inhibitor 1781
Bacillus subtilis 1823
Bacillus thuringiensis toxin 898
 Bacitracin 1472
 BacPac rapid titer kit 1046
 Bacterial activator 381
 Bacterial artificial chromosome (BAC) 656
 Bacteriophages
 – therapeutic use 1751
 Bac-to-Bac 1046
 Bactosomes 1613, 1618
 Bactotryptone 681
 BaculoDirect 615, 1046
 Baculosomes 1613
 Baculovirus transgenic 1046
 Baculovirus expression vector system (BEVS) 1045
 BacVector-3000 105
 Balke protocol 175
 Basic local alignment search tool, *see* BLAST
 Basiliximab 21, 456, 1086
 BAY-14-2222 459
 Baycol 52
 BayerHealthCare pharma biotechnology 1021
 Bayovac CSF E2 26
 BC1 217
 BC200 217
 BCMS 220
 B-cell chronic lymphocytic leukemia 222–223
 B-cell epitopes 1119
 B-cell neoplasia-associated gene with multiple splicing 216
 Bcl-2 317
 – antiapoptotic properties 819
 – Becaplermin 465
 Beckwith-Widemann syndrome (BWS) 219
 Benefix 10, 459
 p-Benzamidine 699
 Benzbromarone
 – CYP2C9 inhibitor 1590
 Benzonase 158
 Benzotriazolyl carbonate 1398
 7-Benzoyloxy-4-trifluoromethylcoumarin (BFC) 1610
 Bergmann reaction 1125
 Beromun 23, 463, 479
 Beta-cyclodextrin 407
 Betaferon 4, 17, 467
 Beta-glucocerebrosidase 861
 Beta-grasp motif 383
 Betaine aldehyde dehydrogenase 976
 Betaine synthesis 977
 Betaseron 17, 467, 1404
 Beta-tryptase 405
 – diketopiperazine-based bibasic inhibitors of 412
 – inhibition by cyclodextrin-based inhibitors 408
 – inhibition by PEG-linked inhibitors 406
 Bevacisumab 143, 455, 479
 – effect by blocking a growth factor 1169
 – cancer treatment 1280
 Bexxar 454–455, 479, 501, 1086, 1121, 1169
 – application 1278
 Bioassay
 – cell culture-based 1565
 – quality characterization of biopharmaceuticals 1565
 Bioclate 10, 454, 459
 Bioequivalence 1756
 Biogamma 467, 479
 Biogenerics 1662, 1728, 1756
 – EU regulations 1700
 – market 1722
 Bioinformatics 255, 1771
 Bioleukin 464, 479
 Biological products regulations 1686
 Biologics license application (BLA) 1126, 1638
 Bioluminescence applications 1224
 Biomarker
 – exploratory 58
 – DNA-based 57
 – genomic 56
 – pharmacogenomic 59
 Biomarker patterns software 1332, 1336
 Biomek 1332
 BioMEMS 1542
 Bionanotechnology 1537
 Biopharmaceutical advantages 1725
 Biopharmaceutical approval
 – for post-translational modification 7
 – for veterinary use 25
 – of proteins engineered products 6
 – PEGylated 1412
 – products for human use 9
 Biopharmaceutical development
 – good manufacturing practice (GMP) 1661
 – regulations 1689

- US federal laws for 1640
- Biopharmaceutical drugs 453
 - approval system in EU 1684
 - BLA/NDA stage 1644
 - classes of 1560
 - design of novel 1775
 - development of 1090
 - EU regulations 1669
 - half life of 1363
 - handling 1570
 - IND stage 1643
 - innovate around existing 1730
 - innovative approaches 1732
 - marketing of 1736
 - PEGylated and kinetic parameters 1403
 - post-approval 1644
 - prescription 1736
 - price increase 1715
 - protect exclusivity of 1730
 - radiolabeling 1251
 - registration and marketing 1697
 - scheme of pharmacokinetics 1365
 - withdrawals from market 1604
- Biopharmaceutical manufacturing
 - common errors in 1659
 - inspectional authorities 1653
 - process validation 1653
 - virus safety 1650
- Biopharmaceutical production
 - from cereal grains 931
 - in culture plant cells 949
 - in the desert 967
 - new cell lines 761
 - using insect cell culture 1045
 - using transgenic animals 995
 - using yeast 1033
- Biopharmaceutical proteins
 - manufacture of recombinant 723
 - PER.C6 779
- Biopharmaceuticals
 - definition 2
 - first generation 1759
 - follow-on market 1729
 - generic threat for 1729
 - global sales 1759
 - veterinary 25
- Bioreactor
 - adherent-cell culture in 739
 - annual output using 10× fed-batch 1092
 - annual output using 10× perfusion 1091
 - batch perfusion 741
 - continuously perfused production 743
 - extended-batch perfusion 741
 - fed-batch 824
 - hollow-fibre 738
 - large-scale transient expression 744
 - moss 919
 - perfusion 1050
 - photo 922
 - preparation of drug metabolites 1622
 - stirred-tank 739, 1050
- Bioreactor process
 - development efforts 750
 - regulatory issues 745
 - risc of bacterial contamination 746
 - risc of viral contamination 747
 - scale-up 740
- Bioseb 1087
- Biosensors 1544
- Biosimilar medicinal product guidelines 1707
- Biostim 463
- Biotech
 - development 1654
 - procedure 1683
 - products registered in EU 1675
- Biotechnological products
 - EU adopted guidelines 1705
- Biotechnology quality working party (BWP) 1670
- BioTropin 14, 476
- Biphasic human insulin 469
- Biphasic insulin aspart 470
- Biphasic insulin lispro 469
- Biphasic porcine insulin 471
- Bispecific T cell engager 1175
- BiSphere 1305
- BiSteel 871
- Bitistatin 1283
- Bivalent ligand binding 396
- Bivalrudin 461
- BLAST (basic local alignment search tool) 105, 108, 255
- BlastX analysis 108
- Blasticidin 666
- Blasticidin deaminase 766
 - marker 767
- Bleeding episodes treatment 441
- Blood-brain-barrier 1771, 1783, 1791, 1795
- B-lymphocyte stimulator 505
- BM185 cell 204
- Bombesins 486
- Bombinins 486
- Bone marrow transplant (BMT) 1757
- Bone morphogenic protein (BMP) 294
- Bongard problem 1773
- Boost Plus 1454

- Boroleucine 1472
 Botulinum type A toxin 463
 Bovine herpes virus (BHV) 27
 Bovine serum albumin (BSA) 269, 957
 Bovine somatotropin 25
 Bovine spongiform encephalopathy (BSE) 747, 1007
 Bovine viral diarrhea virus (BVDV) 434
 Boyden chamber assay 643
 BR96
 – in cancer treatment 1172
 Bradykinins 486
 Bradyphrenia 328
 Brain capillary endothelium 1517
 Brain-derived neurotrophic factor (BDNF) 77
 Brambell receptor 1167
Brassica juncea 977
Brassica napus 973, 977
 Bravelle 464
 Breast cancer 143, 239
 – EGFR-positive 524
 – ER-positive 524
 Breast Cancer International Research Group (BCIRG) 144
 Boehringer Ingelheim high expression system/chinese hamster ovary cell 1094
 Bromfenac 52
 Bromodeoxyuridine (BrdU) 641, 1261
 6-Bromoindirubin-3-oxime 288
 Brutons tyrosine kinase variant (BTK) 1053
 BSE *see* Bovine spongiform encephalopathy
 B-type polymerase
 – structural features of 710
 Buerger's disease 307
 Bullous pemphigoid 1193
 Bundesinstitut für Arzneimittel und Medizinprodukte 1679
 Bupropion, hydroxylation 1618
 Burkitt's lymphoma cell 1029
 Butyrophilin 1205
 Butyrylcholinesterase 870
 Buzerelin 1376
 BYK150640 chemical structure 410
 BYK76935 chemical structure 410
 Bypass graft failure 313

C
 C1I-Immuno 859
 cA2 456
 CABG (coronary artery bypass grafting) 154, 237, 312
Caenorhabditis elegans 571
 Caffeine
 – CYP3A4 activated 1587
 Calcitonin 1376, 1467
 Calcium concentration-time profiles in plasma 1468
 Calf intestinal alkaline phosphatase, *see* cIAP
 Calicheamicin 1125
 Calmette-guerin vaccine 1430
 Calnexin 420, 427
 Calogen 477
 Calreticulin 420, 427, 1435
 Campath 22, 455, 479, 811, 1086
 cAMP (cyclic adenosine monophosphate) 318
 Camptothecin 1367
 Cancer 238
 – therapy 127, 1243, 1276
 – cells, in folate receptor-mediated gene transfer 1515
 – vaccine 864
 Cancer research UK pharmacokinetic and pharmacodynamic technologies advisory committee 1250
Candida albicans 1285, 1435
 Canferon A 468, 480
 Capan-1 1319
 Capecitabine 1252
 Capillary zone electrophoresis (CZE) 162
Capsella bursa pastoris 486
 CAPSIT protocol 347
 Carbamazepine
 – clearance of 1594
 – CYP3A4 activated 1587
 Carbon nanotubes 1548
 Carboplatin 131
 Carbopol 1380
 Carboxyfluorescein 1467, 1480
 Carcinoembryonic antigen 1123, 1234, 1277
 Cardiac specific proteins 290
 Cardiac transcription factors 290, 293
 Cardiac troponin 293
 Cardiomyocytes 289, 320
 – clinical applications of hES derived 293
 – differentiation system 293
 – enrichment and purification 298
 – hES cell derived 292
 Cardiopulmonary bypass
 – trials with rhAT 1011
 Cardiovascular disease 305
 – pathways and targets for 625
 – targeting 1281
 CaroRx 865
 Caruleins 486
 CASE 1624

- Casein 998
 - peptone 681
- Caspase activation assay 644
- Catechol-O-methyltransferase 330
- Catharanthus roseus* 950
- Cathelicidins 1433
- Cathepsin B 1282
- Cathepsin B2 1285
- Cathflo Activase 461
- Cationic liposomes 1510
- Cationic antimicrobial peptides 1419
 - artificial 1433
 - as vaccine adjuvants 1433
 - subgroups 1433
- Cationic peptides
 - delivery system 1419, 1437
 - vaccine adjuvant 1426
- CATS descriptors 1797
- CB03 769
- CD105 1281
- CD20 1278
- CD25 20
- Cdc13 43
- Cdc13p 40
- CEA-scan 21
- C/EBP 233
- Celeuk 463, 479
- Cell concentration
 - maximum 816
 - viable 816
- Cell cycle
 - manipulation of 820
 - mutants 822
- Cell engineering 819
- Cell free reaction
 - pH 1073
- Cell graft 295
- Cell line
 - generation 727
 - generation timeless 788
 - regulations for qualification 1645
 - stability 818
- Cell migration 642
- Cell (specific) perfusion rate (CSPR) 794
- Cell proliferation 821
- Cell retention device 1087
- CellBag
 - cultivation of Sf-9 cells in 1056
- Cellferon 467
- Cellular lactate dehydrogenase 1427
- Cellular transformation 642
- Celmoleukin 463, 479
- Centaxarin 458
- Center for drug evaluation and research (CDER) 49, 1765
- Center for food safety and applied nutrition (CFSAN) 1639
- Center for veterinary medicine (CVM) 1639
- Center of biologics evaluation and research (CBER) 1639
- Center of devices and radiological health (CDRH) 1639
- Center of disease control 1752
- CenTNF 456
- CentoRx 462
- Centoxin 455, 1117
- Central nervous system 1791
 - active drugs 1794
- Centuximab 455
- Ceprotin 454, 457
- CeramTec 681
- Ceredase 475, 862
- Cerezyme 8, 23, 475, 862
- Cerius 1610
- Cerivastatin 52
- Certification of suitability 1680
- Certoparin sodium 457
- Cetrolix 476
- Cetrotide 476
- Cetuximab 479, 1121
- cGMP (current good manufacturing practice) 749, 949, 1126, 1641, 1654, 1661
- Chaperones 1072, 1074
- Cheloidonium maius* 482
- Chemical exchange-dependent saturation transfer 1217
- Chemistry manufacturing and control (CMC) 1126
- Chemotherapy 1272
- Chimeric antibody 7, 1109, 1153
- Chimeric mice 657
- Chitin 1374
- Chitosan 1374, 1380
 - solution 1378
- Chlamydomonas reinhardtii* 898
- Chloramphenicol acetyl transferase (CAT) 1075, 1532
- Chloronema* cell 920
- 4-(4-Chlorophenyl)imidazole
 - CYP2B4 inhibitor 1597
- Chloroxozone hydroxylation 1618
- CHO (Chinese hamster ovary cell) 433
 - cell line 762
 - quality control 435
- Cholesteryl ester transfer protein (CETB) 78
- Cholesterylhemisuccinate 1523

- Choline dehydrogenase 977
 Choline monooxygenase 976
 Choline oxidase 977
 Choriogonadotropin alfa 477
 Chromatographic assay 164
 Chromatographic methods
 – for analytical properties of biopharmaceutical material 1562
 Chromogenic ISH (CISH) 134
 Chromogenics kit 1006
 Chronic disease era 103
 Chronic myeloid leukemia treatment 506
 Chronic myocardial ischemia 151
 Chronic obstructive pulmonary disease 1344
 – IMS chromatogram 1351
 Chrysamine G 1287
Chrysanthemum morifolium 894
 Chymotrypsin, inhibition by aprotinin 1027
 Cialic acid 772
 cIAP (calf intestinal alkaline phosphatase) 714
 – expressibility of, in *E. coli* 714
 – variance of 714
 3,4,5-Cimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide, *see* MTT
 Cimetidine
 – CYP2C9 inhibitor 1590
 CIPHERgen biomarker 1338
 CIPHERgenExpress 1332
 Circular dichroism
 – conformation of hAT analyzed by 1004
 – insulin proteolysis investigated by 1474
 Circulins 484
 Cisapride 52, 1605
 Cisplatin 131, 136, 1250
 Citrullinated peptide antibodies, anti cyclic 1189
 Cleactor 461
 Clean in place (CIP) 746
 Clexane 457
 Clinical trial assay (CRA) 133
 Clinical trial authorization application (CTA) 1697
 Clinical trial protocol (CTP) 1697
 Clivarine 457, 1750
 Cloning
 – reproductive 365
 – therapeutic 365
 ClustalW algorithm 110
 CMPD 220
 c-Myc 42
 Coagulation 377
 – factors 379
 Coagulation factor IXa, *see* fIXa
 Code of federal regulations (CFR) 1641
 Coded spheres 84
 Codeine 57
 – metabolized by CYP3A4 1585
 Codon
 – adaptation index 1023
 – usage, of IL-4v gene 1024
 Cognate factor VIII 743
 Collagen 872
 – matrix assay 643
 – induced arthritis 235
 Collimator types 1220
 Colony-stimulating factor (CSF) 466
 Combinatorial chemistry (CC) 101
 Comet assay 1626
 Committee for proprietary medicine products (CPMP) 434, 1670, 1675
 Committee for human medicinal products (CHMP) 1670, 1678
 Committee for orphan medicinal products (COMP) 1678–1679
 Committee for veterinary medicinal products (CVMP) 1678
 Common technical document (CTD)
 – electronic 1699
 – format 1698
 Complete Freund's adjuvant 194
 Complex disease 77
 Computer-aided drug design (CADD) 1607
 Comvax 18
 Concanavalin A 484
 Confocal image assisted 3-dimensionally integrated quantification (CIDIQ) 1526
 Congestive heart failure (CHF) 318
 Congo Red 1287
 Connective tissue disease (CTD) 1750
 Connexin43 320
 Connexin45 292
 Constitutive androstane receptor (CAR) 1788
 Contergan 1675
 Continuous (chemostat) perfusion cell 430
 Contract manufacturing
 – client contracting 1095
 – integrating 1089
 Contract manufacturing organization (CMO) 1083, 1093
 Contrast agents
 – for imaging modalities 1213
 – for molecular imaging 1225
 – for optical imaging 1223
 – for SPECT 1222
 – for ultrasound imaging 1219
 – smart ultrasound 1303
 Copper bis-thiosemicarbazones 1264

- CORINA program 1777, 1797
 Corixa 502
 Coronary artery bypass grafting, *see* CABG
 COSMIC program 1797
 Costilate 473
 Coulyflower mosaic virus 894, 954, 981
 Coumarin hydroxylation 1618
 CpG-ODN 1424
 CRA-2059 chemical structure 407
 Creatine phosphate 1075
 CREB phosphorylation 1746
 Creon 860
 Crescormon 476
 CRESTOR 55
 Creutzfeld-Jakob disease 424, 747, 872
 – new variant 1007
 – pathways and targets for 627
 Critical flooding temperature 1316
 Crohn's disease 21
 – fragment for treatment 1116
 Cross-fire effect from beta particle emitters 500
Cryptococcus neoformans 686
 Cryptotope 1191
 cTnI 290
 Current good manufacturer practice, *see* cGMP
 Cyanovirin 1406
 – immunologic response in mice 1407
 Cyanovirin-N 483
Cycas revoluta 484
 Cyclic adenosine monophosphate, *see* cAMP
 Cyclic response element 233, 239
 Cyclin-dependent kinase 219, 821
 Cyclin kinase inhibitor 763
 Cyclo18 256
 Cyclo50 256
 Cyclo66 256
 Cyclo80 256
 Cyclodextrin 407
 Cyclohexylalanine 413
 Cyclohexylglycine 413
 Cyclophilin-B 257
 Cyclophosphamide 503
 – hydroxylation catalyzed by CYP2B4 1597
 Cyclosporine 55, 58
 – metabolized by CYP3A4 1585
 Cycloviolins 484
 CYP gene testing kit 78
 CYP102 1609
 CYP17A 1616
 CYP17A1 1616
 CYP1A2 1618, 1621
 – molecular model 1612
 CYP1B1 1620
 CYP2A6 58, 1618, 1621
 CYP2B 121
 CYP2B4 1621
 – apo-form 1598
 – inhibitors 1597
 – structure of 1597
 CYP2B6 58, 1618
 CYP2C19 57, 61, 76, 1618, 1620
 – molecular model 1611
 CYP2C3
 – chimeric 1595
 – isoforms 1595
 CYP2C5 1610
 – Co-complexes 1596
 CYP2C8 58, 1609, 1618
 – active sites 1594
 – inhibitors 1594
 – pharmacophore 1595
 CYP2C9 57, 76, 1609, 1618
 – crystal structures 1590
 – flurbiprofen complex 1591, 1593
 – in drug metabolism 1590
 – inhibitors 1590
 – isoforms 1589
 – molecular model 1611
 – S-warfarin complex 1591
 CYP2D6 51, 57, 61, 76, 1618, 1620–1621
 – molecular model 1611
 CYP2E1 1615, 1618
 CYP3A 121
 CYP3A4 54, 58, 1584, 1615, 1618, 1788
 – activity 1587
 – allosteric nature 1586
 – Co-complex structures 1588
 – isoforms 1584
 – molecular model 1610
 – structure of 1585
 – subfamily 1585
 CYP3A5 58, 1618
 Cysteine knot motif 484
 Cysteine thiols 1400
 Cystic fibrosis 1751
 Cytochrome metabolism 1609
 Cytochrome P450 76, 329
 – active site 1584
 – bacterial expression of human 1615
 – classification 1582
 – crystal structures 1581
 – genetic polymorphism of human 1583
 – GloTM-assay system 1613
 – microsomal 1581
 – prokaryotic 1584
 – structure of soluble 1584

- Cytochrome P450, human
 – associated with drug metabolism 1617
 Cytochrome P450 reductase (CPR) 1615
 Cytodex 739
 Cytogenetics of CHO cell lines 735
 Cytokine immunostimulatory 1173
 Cytolytic T lymphocytes 1489
 Cytomegalovirus (CMV) 188, 1489
 – enhancer 299
 – human 764
 – promoter 156
 Cytopathic effect 166
 Cytoplasmic microinjection 1531
 Cytotoxic T lymphocytes 199, 1175
 Cytotoxicity
 – antibody dependent cellular 1107, 1156, 1274
 – complement dependent 1107
 – cell-mediated 924
- d**
 1D09C3 (anticancer antibody) 1177
 Daclizumab 21, 456, 1086
 Dalteparin sodium 457
Danau plexipis 1047
 Darbepoietin 16
 Darbepoietin alfa 472
 DARWINIZER 1779
 Dash 84
 Daudi B-cell lymphoma 526
 Daunomycin 1814
 Daunorubicin 1370
 DD3 gene 220
 DEAE chromatography 166
 DDAB, *see* Didodecyltrimethylammonium bromide
 DEBS (6-Deoxyerythronolide B synthase) 1813
 DEBS system 1815
 DEBS AT module 1815
 DEBS pathway 1819
 DEBS1 1816
 DEBS2 1816
 DEBS3 1817
 Decay accelerating factor (hDAF) 355
 Decoy oligodeoxynucleotides, *see* dODN
 Deep brain stimulation 331
 Deep-vein thrombosis
 – trials with ATryn 1011
 Defensins 383, 486, 1433
 Defibrotide 461
 Dehybridization detection 86
 Dehydration response element 981
 Dehydrobenzene 1125
 Dehydrofolate reductase, *see* DHFR
 Denaturing high-performance liquid chromatography (D-HPLC) 86
Denileukin diftitox 456, 480
 Deoxycoformycin (dCF) 429
 6-Deoxyerythronolide B synthase, *see* DEBS
 DepoInterferon alpha 468, 480
 DEREK 1624
 Dermatan sulfate 458
 Dermorphins 486
 Desirudin 462
 Desmin 290
 Desmopressin 1376
 Desoxyribonucleic acids, *see* DNA
 Dexamethasone 896
 Dexfenfluramine 52
 Dextromethorphan hydroxylation 1618
 DGCR5 220
 D-HPLC, *see* denaturing high-performance liquid chromatography
 DHFR (Dehydrofolate reductase) 725, 1079
 – CHO system 812
 – expression system 813
 – generation of stable cell lines 733
 Diabetes 1445
 – latent autoimmune in adults 1198
 – type 1 1033, 1451
 – type 1 treatment 1454
 – type 2 1033, 1446
 Diabetes Control and Complications Trial (DCCT) 1446
 Diabetes mellitus 13
 – pathways and targets for 626
 – treatment 1473
 Diabetes patients
 – meal study in type 1 1455
 – meal study in type 2 1456
 Diagnostic assay multi-marker-based 1325
 Diagnostic protein
 – directed evolution 705
 – rational design 705
 Diatin 476
 Diazepam 61
 – CYP3A4 activated 1587
 – metabolized by CYP2C9 1590
 6-Diazo-5-oxo-L-norleucine *see* DON
 Diboterminal alfa 464
 Dicer ribonuclease 222
 Dicaloganglioside 1173
 Diclofenac
 – CYP2C5 co-complex 1596
 – hydroxylation 1618
Dictyostelium discoideum
 – in biomedical research 685
 – cells 665
 – retrotransposon 689

- 6A,6D-Dideoxy-6A,6D-diamino-beta-cyclodextrin 407
- Didodecyltrimethylammonium bromide (DDAB) 1508–1509
- Diethyl maleate 1466
- Diethylentriaminepentaacetate 1123
- Diffuse optical tomography (DOT) 1223
- DiGeorge syndrome 220
- Digitalis 835
- Digoxin 58
- N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide 1250
- Dimethylsulfoxide 957
- Dioleoylphosphatidylethanolamine (DOPE) 1508–1509, 1523
- N-[1-(2,3-Dioleoyloxy)propyl]N,N,N-trimethylammonium chloride, *see* DOTMA
- Diphenhydramine 61
- Diphtheria 18
- Directed molecular evolution 709
- DISC1 (disrupted in schizophrenia 1) 221
- DISC2 (disrupted in schizophrenia 2) 220
- Disease
 - genes 73
 - classes of 1276
- Disintegrins 1283
- Disseminated intravascular coagulation (DIC), sepsis induced 997
- Dithiothreitol (DTT) 1073
- Dixon test 168
- DLG2 221
- 6-DMAP (6-dimethylaminopurine) 272
- DMEM (Dulbecco's modified eagle medium) 740
- DMRIE-C transfection reagent 1030
- DNA (deoxyribonucleic acid) 628
 - dumbbell 1532
 - exogenous 1529
 - fragmentation assay 644
 - linear template 1067
 - microarrays 672
 - naked 1490
 - release kinetic 1497
 - residual 167
 - shuffling 590, 706
- DNA databank of Japan (DDBJ) 255
- DNA plasmid
 - conformation of release 1498
 - release kinetics from microspheres 1498
- DNA polymerase
 - engineering of enzymatic activities 711
- DNA vaccination 199
 - for tumor suppression 1501
- DNA vaccine delivery 1487, 1490
 - polymers for 1491
 - efficacy 1489
 - incorporated in polymer microspheres 1492
 - mechanism of action 1489
- DNA-vector complex 1490
- Docetaxel 131, 141, 1251
 - in cancer treatment 1172
- dODN (decoy oligodeoxynucleotide) 231
 - therapeutic application 232
- Dolabella auricularia* 482
- Dolabellin B2 486
- Domperidone 1795
- DON (6-diazo-5-oxo-norleucine) 537
 - antitumor effect of 538–539
 - efficacy of 539
 - inhibition of sarcoma 180 tumor cell growth 541
 - treatment of mouse tumors 541
 - tumor cell line sensitivity 539
- Dopamine producing cell, transplantation of human non-neural 333
- Dopamine transporter (DAT) gene 329
- DOPE, *see* dioleoylphosphatidylethanolamine
- Doppler effect 1218
- Doppler frequency shift 1218, 1304
- Doppler image, two-dimensional 1315
- Doppler mode 1308
- Doppler ultrasound imaging 1238
- Dornase alfa* 475
- Dose determination 1566
- DOTA-biotin 514
- DOTMA (N-[1-(2,3-Dioleoyloxy)propyl]N,N,N-trimethylammonium chloride) 1508–1509
- Double stranded RNA, *see* dsRNA
- Double emulsion technique
 - preparation of microcapsules 1373
- Doxorubicin 131, 1253, 1370, 1814
 - in cancer treatment 1172
 - use 1804
- DoxoRx 866
- DRAGON descriptors 1797
- Drotrecogin alfa (activated) 465
- Drug
 - biopharmaceutical 453
 - development 54
 - labeling 63
 - therapeutic range 54
- Drug classes
 - central nervous system active 1792
- Drug conjugates
 - low molecular weight 1171
- Drug costs 1717
 - cost-benefit evaluation 1720

- cost-conscious prescribing 1721
 - in America 1717
 - in Europe 1717
 - population ageing, impact on 1718
 - price reduction 1719
 - pricing pressure 1724
 - R&D spending 1723
 - Drug delivery
 - bionanotechnology in 1540
 - with ultrasound 1315
 - Drug delivery system 1361
 - administration sites for 1364
 - bucal 1379
 - colon specific 1381
 - conjugates for 1366
 - forms of 1369
 - nasal 1377
 - non invasive 1375
 - oral 1380
 - PEG in 1393
 - pulmonary 1378
 - polymer based 1361
 - transdermal 1382
 - Drug development 1147
 - molecular imaging for 1230
 - P450 for 1582
 - phases in 1231
 - protein kinase in 639
 - siRNA based 264
 - Drug discovery
 - basic concepts of virtual 1773
 - phases 1774
 - Drug discovery process
 - cell based assay 640
 - for chronic disease 100
 - Drug-drug interaction 1787
 - metabolic prediction 1621
 - Drug evaluation and research (CDER) 1639
 - Drug interaction 60
 - effect of genotypes on 61
 - Drug metabolism 1608, 1787
 - contribution of genetic polymorphism to 57
 - CYP2C9 in 1590
 - CYP3A4 in 1584
 - Drug metabolizing enzymes 52
 - Drug metabolites 1622
 - Drug product 1561
 - Drug release by ultrasound 1316
 - Drug response 50
 - Drug substance 1561
 - Drug substances coordinating committee (DSCC) 1765
 - Drug target validation 110
 - necessary cause model 114
 - sufficient component cause model 113
 - Drug therapy for Parkinson disease 329
 - dSLIM (double-stem loop immunomodulator) 183
 - application of 198
 - immunization pathways using 200
 - production 197
 - properties 197
 - dsRNA (double stranded RNA) 244
 - *in vitro* dicing 631
 - Dukoral 19
 - Dundee P450 system 1614, 1619, 1623
 - Duract 52
 - Duteplase 462
 - Dynamic light scattering 162
 - Dynepo 472
 - Dyskeratosis congenita* 41
 - Dyskinesia 332
 - Dysport 463
- e**
- E1 protein
 - induced cell proliferation 782
 - of human adenovirus 782
 - E1A protein 783
 - E1B protein 783
 - E2F 233
 - Ebstein-Barr virus 1029, 1153
 - Ebiratide 1469
 - EBNA1 (Epstein-Barr virus nuclear antigen)
 - expression 1029
 - Ebola virus 484, 1407, 1488
 - Echogen 1305
 - Echovist 1305
 - Ecokinase 11, 462
 - Econazole 1370
 - Ectoine synthesis 978
 - Edrecolomab immunotherapy 1278
 - Efalizumab 456
 - Efavirenz 58
 - EGF (epidermal growth factor) 238, 463
 - EGFR (epidermal growth factor receptor) 59, 105, 623
 - Elastase 380
 - Elcatonin 476
 - Elcitonin Inj. 20S 476
 - Electromechanical (NOGA) mapping 155
 - Electron spray ionization (ESI) 1564
 - Electronic standards for transmission
 - of regulatory information (ESTRI) 1699
 - Electrophoretic methods
 - in quality control 1563

- Electroporation 1382
 - DNA transfer into mammalian cells 729
- ELISA (enzyme-linked immunosorbent assay) 166, 168, 172, 1563
 - characterization of antibodies by 797
 - of soluble protein from rice grain 940
 - protein levels of rhVEGF measured by 923
 - sandwich 1564
- ELISpot responder rate 1432
- Elitec 475
- Elitex 24
- Ellman reagent 1415
- Elspar 537
- ELUTES trial 315
- Embryoid body 286
- Embryonic antigen 288
- Embryonic development 287
- Embryonic germ (EG) 278
- Embryonic renal progenitor 357
 - organogenesis 366
- Embryonic stem (ES) 269
- Embryonic stem cell 286, 319
 - cardiomyocyte differentiation 289
 - characterization of human SCNT 276
 - human 269, 287
 - marker 276
- Embryotoxicity
 - use of *D. discoideum* for testing 687
- Emend 1538
- Eminase 461
- Enbrel 7, 24, 463, 1118
- Encephalomyocarditis virus 766
- Encoded self-assembling chemical libraries (ESACHEL) 1275
- End stage renal disease (ESRD) 354
- Endocytosis 1426, 1490
- Endoglin 1281
- Endosomal escape 1530
- Endosperm cell 935
- Endothelial cell adhesion molecules 1282
- Endothelial progenitor cell (EPC) 285, 319
- Endotheline 235
- Endotoxemia 1009
- End-point dilution (EPD) assay 166
- Engerix B 18, 1639
- Enhanced permeability and retention effect (EPR) 1366
- Eniluracil 1253
- 5-Enolpyruvyl-shikimate3-phosphate synthase 898
- Enoxaparin 457
- Enterobacter aerogens* 1352
- Enterodiol 943
- Enterolactone 943
- Entrez Gene 255
- Enzymatic degradation 1363
- Enzyme 474
 - activity, imaged by NIR 1283
 - drug-metabolized 1608
 - endoproteolytic 1194
 - mutant 711
 - strategy for evolution directing 706
 - wild type 711
- Enzyme immunoassay test (EIA) 1190
- Enzyme-linked immunosorbent assay, *see* ELISA
- EpCAM 1278
- Epidermal growth factor, *see* EGF
- Epidermal growth factor receptor, *see* EGFR
- Epirubicin 131
- Epithelial cellular-adhesion molecule 862
- Epitope 1190
 - blocking 1163
 - classification 1191
 - continuous 1192
 - continuous helical 1193
 - cryptic 1197
 - discontinuous 1194
 - linear 1195
 - mapping 1192
 - post-translationally modified 1192
 - proteinaceous 1193
 - specificity 1163
 - visualization 1195, 1198
- Epoad 472
- Epoetin delta 472
- Epogen 3, 16, 472, 738
- Epogen Herceptin 737
- Epogin 472
- Epopen 472
- Epothilone 1804
- Eprex 472, 1656–1657, 1762
- ErbB1(epidermal growth factor receptor) 129
- ErbB2 129
- ErbB3 129
- ErbB4 129
- Erbitux 454–455, 479, 1121
- ERGIC-53 420
- Ergotamine 330
- Erlotinib 143
- Erypo 472
- Erythrocytes 1173
- Erythroid membrane associated protein 1205
- Erythromycin
 - biosynthesis steps 1811
 - by DEBS'3 1815
 - derivatives 1813

- metabolized by CYP3A4 1584
 - pathway 1821
 - use 1804
 - Erythropoietin (EPO) 466, 737
 - Erythropoietin alfa 472
 - Erythropoietin beta 472
 - Escherichia coli* 1135, 1351, 1401
 - cell free expression of biopharmaceuticals using 1063
 - expression platform 1022
 - extracts 1070–1071
 - G-CSF produced by 1757
 - in biosynthesis of insulin 1034
 - plasmid DNA templates for 1066
 - transgenic genomes from 1046
 - Escherichia coli* system
 - coupled transcription/translation from 1076
 - reaction conditions 1075
 - Esperamycin 1125
 - Espo 472
 - Est1p (ever shorter telomeres) 40
 - Est2p 39
 - Est3p 40
 - Estrogen response element 233, 239
 - Etanercept 463, 1118, 1163
 - Ethoxyresorufin 1618
 - Ethyl-(diamethylaminopropyl)carbodiimide 1310
 - Ethylenediamine tetraacetic acid 1466
 - N-Ethylmaleinimide 403
 - Etoposide 131, 503
 - EU authorities
 - bioproduct definition 1681
 - EU concept papers 1706–1707
 - EU directives 1703
 - EU draft guidelines 1706–1707
 - EUDRACT database 1697
 - EUDRAlex 1670, 1677, 1682
 - EUDRANet 1677
 - EUDRATrack 1677
 - EudraVigilance 1677
 - EU guidelines
 - adopted for biosimilar medicinal products 1707
 - adopted for biotechnology medicinal products 1705
 - Euglycemic clamp study
 - dose ranging 1451
 - Eukaryotic transcription factor 235
 - EU regulations 1703
 - for biopharmaceuticals 1669
 - laws 1676
 - Eurifel FELV 26
 - Eurifel RCPFEVL 26
 - European bioinformatics institute 255
 - European commission (EC) 1760
 - European community pharmaceutical directive 1675
 - European council regulation 1677
 - European department for the quality of medicine (EDQM) 1680
 - European federation of pharmaceutical industries and associations 1643
 - European market, generic conversion rates and price 1766
 - European medicines evaluation agency (EMA) 434, 1559, 1643, 1677
 - key tasks 1678
 - European molecular biology institute 255
 - European nutrigenomics organization 93
 - European organization for the treatment of cancer (EORTC) 1233
 - European pharmacopoeia 1680
 - European public assessment report (EPAR) 1688
 - EuroPHARM database 1677
 - Evalizumab 1086
 - Evans blue 1472
 - Exercise treadmill test (ETT) 175
 - Exogenous DNA 1529
 - Exon 2 653
 - Exopeptidase 1379
 - Expanded bed absorption
 - biopharmaceutical production in cultured plant cells 960
 - Experimental autoimmune encephalomyelitis (EAE) 1237
 - Expressed sequence tag (EST) 105, 630
 - Expression difference mapping 1330
 - ExpressTec 931
 - development 933
 - protein expression in grains 945
 - Extracellular matrix
 - imaging 1256
 - modified 1276
 - Extracellular superoxide dismutase (ecSOD) 317
 - Extrachromosomal palindrome 664
- f**
- fVIIa 459
 - fVIII 459
 - biosynthesis 427
 - by perfusion technology 743
 - development of recombinant 428
 - production of recombinant 430
 - protein 424
 - secretion and activation 426

- structure and function 425
- fIX 495, 695
- activated 699
- human 459
- protein, exon, domain and structure of 696
- zymogen form 697
- Fabrase 475
- Fabrazyme 23, 475
- Fabry disease 23, 861
- pathways and targets for 625
- fC 459
- FACS, *see* fluorescence-activated cell sorting
- FANTOM2 dataset 217
- Fasturtec 24, 475
- Fatty acid oxydation 121
- FCGR3A 59
- FDA, *see* Food and Drug Administration
- FD&C Act 1641
- Feline immunodeficiency virus (FIV) 202, 556
- Fenfluramine 52
- Feron 467
- Fertinex 464
- Fertinorm 464
- Fetal bovine serum (FBS) 785
- Fevaxyn Pentofel 25
- Fexofenadine 58, 1788
- FGF (fibroblast growth factor) 153, 307
- FGF-4 172
 - pACSR/FGF-4 156
 - proteine, production of 168
- FGF-5 172
- Fibrin 1283
- Fibrin clot lysis assay 1565
- Fibrinogen 1283
 - expression of, in rice grain 940
 - recognition exo-site 413
 - recognition site 412
- Fibrinolysis 377, 1009
- Fibronectin 738, 1283
- Fiducial limit 168
- Field flow fractionation, *see* FFF
- Filgrastim 4, 16, 473, 1406, 1755
- Firefly luciferase 1228
- FirtEF algorithm 108
- FISH (fluorescence *in situ* hybridization) 134, 728, 736
 - analysis of BC6 transgene 1002
 - semiquantitative 1002
- FK506 1805
- Flavodoxin 1616
- Flock haus virus (FHV) 263
- Fluconazole
 - CYP2C9 inhibitor 1590
 - radiolabeled 1285
- Fluoracil 510
- 5-Fluorouracil 76
- Fluorescein isocyanate 1472
- Fluorescein isothiocyanate (FITC) 363
- Fluorescein isothiocyanate-Tat-Peptide 637
- Fluorescence-activated cell sorting (FACS) 299, 1112, 1431
 - for screening of cell lines 816
- Fluorescence-mediated tomography
 - protease activity imaging 1282
- Fluoro-deoxy-arabinofuranosyl-iodouracil (FIAU) 1254
- Fluorodeoxyglucose 499, 1226
- Fluoroestradiol 1256
- Fluoroethanidazole 1264
- Fluoroethylpiperone (FESP) 1254
- [(Fluorohexenyl)benzene-sulfonylamino]-3-butyric acid 1257
- (Fluoro-hydroxy methyl butyl) guanine 1254
- Fluoro-methyldeoxyuracil-arabinofuranoside 1261
- Fluoromizonidazole 1264
- Fluorophores 1227
- Fluorothiol 1259
- Fluorothymidine 1261
- Fluorouracil 131, 1250
 - radiolabeled 1253
- Fluoxetine 61
- Flurbiprofen
 - CYP2C9 complex 1593
 - metabolism 1593
- Fluvoxamine 61
 - Fluxum 457
- Follicle-stimulating hormone (FSH) 4
- Follistim 15, 465
- Follistim AQ 465
- Follitropin alpha 463
- Follitropin beta 465
- Fondaparinar sodium 457
- Food and drug administration (FDA) 49, 1559, 1639, 1765
 - guidance 1642
 - regulatory authority for monoclonal antibodies 1085
- Forcalcitonin 477
- Forcaltonin 15
- Formivirsen 24
- Forskolin 292
- Forsteo 15, 477
- Forteo 15, 476
- Fortical 477

- Fourier transform ion cyclotron resonance (FTICR) 1564
- FP-TDI 84
- Fractogel-DEAE chromatography 158
- Fragment antigen binding 1088
- Fragmin 457
- Fraxiparine 457
- Fraxodi 457
- Free induction decay (FID) 1216
- Freud's adjuvant, complete 194
- Frone 467
- 1,2-Fucosyltransferase 355
- 3-Fucosyltransferase 925
- Fusigenic-hemagglutinating-virus 307
- Fusogenic lipids 1523
- g**
- G protein-coupled receptor (GPCR) 664
- G418 299, 785
- GA (glutaminase-asparaginase) 540
- inhibition of sarcoma 180
 - tumor cell growth 541
 - treatment of mouse tumors 541
- Gag proteins 551
- Galactosidase 1500
- 3-Galactosyltransferase 355
- 4-Galactosyltransferase 925
- Gallivac HVT IBD 26
- Gamma-aminobutyric acid (GABA) 1198
- Gamma scintigraphy of oralin deposition 1450
- Gancyclovir 313
- GAP31 482
- Gas chromatography/mass spectrometry (GC/MS)
- of Mathay resinol 945
 - in lung cancer detection 1344
- Gastric lipase deficiency 859
- GATA4 290
- Gateway bacteriophage 610
- Gateway cloning 614
- three-fragment multisite 618
- Gateway-enabled baculovirus expression system 615
- Gateway entry clones 611
- Gateway, multisite 616
- Gateway reactions 610
- Gateway recombinatorial cloning system 606
- Gateway vector system 611
- Gaucher's disease 8
- G-CSF (granulocyte colony-stimulating factor) 4, 321, 1755
- dosage 1757
 - function 1757
 - PEGylation 1404
 - PEGylation sites and relative yields 1405
 - production 1756
- Gefitinib 59, 76
- Gelatin 872, 957, 1380
- microcarriers 336
- Gemeinsamer Bewertungsausschuss 1720
- Gemfibrozil
- CYP2C8 inhibitor 55, 1594
- Gemtuzumab 455
- Gemtuzumab ozogamicin 480, 1086
- in cancer treatment 1172
- Gemtuzumab zogamicin 22
- Genasense 633
- GenBank sequence 170
- Gene structure
- analysis of 651
- Gene amplification 733
- Gene cloning, full length 109
- Gene correction 1531
- efficiency 1534
 - site specific 1533
- Gene delivery 153, 1318
- bionanotechnology in 1543
 - liposomal 1507
 - scheme for hepatocyte selective 1512
 - system 1521
- Gene expression
- heterologous 769
 - chip 1613
 - heterohybridoma 769
- Gene identification 105
- Gene mining
- *de novo* prediction 107
 - homology/orthology mining 105
 - *in silico* prediction 107
 - integrated approaches 108
 - splice variants 108
 - transcript 107
- Gene recombination 706
- Gene replacement (knock-out) 666, 669
- at predefined locus 767
- Gene silencing 258
- antisense oligos 633
 - antisense RNA 633
 - post transcriptional 634, 896
- Gene targeting
- in CHO cells 768
 - genetically modified mice 651
- Gene therapy 31, 1521
- adenovirus-based 151
 - and regenerative cardiovascular medicine 319
 - cytotoxic 313

- DNA-based molecules for 183
- for cardiovascular disease 305
- for myocardial failure 318
- for myocardial protection 317
- of AIDS 553
- radiation 313
- somatic 689
- therapeutic angiogenesis 307
- vector 155, 184
- Gene transcription 933
- Gene transfer 733
 - anti-thrombogenic 315
 - cationic 1510
 - for rapid re-endothelialization 314
 - in cancer cells 1515
 - nitric oxide 314
 - to brain 1517
 - to prevent matrix remodeling 315
- Gene trap 669
- GeneChips 84, 1750
- Gene-environment interactions 75
- Generic biopharmaceuticals 30
- Generic conversion rate 1766
- Generic price 1766
- Gene-targeted mice 658
- Genetic background 73
- Genetically modified mice 649
- Geneticin 785
- Genetonorm 476
- Genome analysis 170
- Genome-wide variant pattern (GVP) 80
- Genomic information
 - translation of 83
- Genomics 30
- Genosensors 1545
- Genotoxicity
 - *in silico* 1624
 - *in vitro* 1624
 - prediction 1624
 - screening 1627
- Genotropin 14, 476
- Genotropin Miniquick 476
- GenScan mining 108
- Gentel 463
- Geref 476
- Gibberellic acid 957
- Ginkgo biloba* 61
- Gleevec 639
- Glial fibrillary acidic protein promoter 1517
- Glial-derived nerve growth factor (GDNF) 333
- G-line 772
- Glioblastoma multiforme 509
- Gliptide 463
- Globuren 472
- Glomerular basement membrane 1197
- Glucagen 14
- Glucagen 476
- Glucagon G Novo 476
- Glucagon rDNA 476
- Glucocerebrosidase 861
- Glucose
 - concentration-time profile in plasma 1471, 1476
 - concentration after kitosan capsule administration 1483
- Glucose metabolism
 - PET imaging of 1260
- Glucosidase 861
- GlutaDON therapy 537
- Glutamate decarboxylase 65
 - modeling 1198
- Glutamate synthetase 734
- Glutamic acid carboxylase 905
- Glutaminase synthetase, *see* GS
- Glutaminase asparaginase, *see* GA
- Glutamine synthetase (GS)
 - expression vector 812
 - /CHO cell system 1094
- Glutathione
 - reduction in transgenic plants 979
 - reductase 1073
- Glutelin 933
- gly 219 700
- Glyburide 1457
- Glycan analyse 800
- Glycan structure
 - differences in 773
- Glycinebetaine 976, 988
- Glycogen synthase kinase 3 inhibitor 288
- N-Glycolyl neuraminic acid 772, 811, 849
- Glycosylation 678
- Glycosyl phosphatidylinositol (GPI) 674
 - anchor 716
- Gold in drug delivery 1540
- Gold standard 87, 201
- Golgi apparatus 427
- Gonadorelin 1376
- Gonal F 9, 15, 463
- Good laboratory practice (GLP) 1640
- Good manufacturing practice (GMP)
 - in transgenic systems 851
- Goodpasture disease 1197
- Goserelin 478
- Gosher's disease 23, 1513
 - test on enzyme therapy 905
- Government printing office 1640
- GPS (Global Pharma Specialist), XXV 1833

- G-protein coupled receptor (GPCR) 105
 Gram-negative pathogen 686
 Gram-negative bacteria 485
 Gram-positive bacteria 381, 485
 Gran 473
 Granocyte 473
 Granulocyte-colony stimulating factor, *see* G-CSF
 Granulocyte-macrophage colony-stimulating factor (GM-CSF) 6, 1429
 Granulokine 473
 Graves disease 1188
 Green fluorescent protein reporter 1627
 GreenScreen 1608
 GreenScreen GC 1624
 – assay 1630
 – genotoxicity tests 1627
 – industrial validation studies 1633
 – molecular genetics 1628
 – proof of concept 1631
 Grepafloxacin 52
 Growject 476
 Growth factor 154
 GRTPA 461
 GS (Glutamine synthetase) 809
 – schematic of a cell line selection program 817
 GS-CHO cell lines 812
 GS-NS0 cell lines 812
- h**
- H19 220, 277
 HA-1A 455
 HAART (highly active antiviral therapy) 549, 558
 Haemate HS 454, 459
 Haemate P 459
Haemophilus influenzae 1421
Haemophilus influenzae B 18
 Hairy cell leukemia 17
Haliclona cratera 482
Halomonias elongata 978
 Ham F12 740
 HAMA 7
 Hamster antibody production test (HAP) 434
 HANC 220
Hansenula polymorpha 1135
 Hapase 461
 Haplotype blocks 81
 Haplotype tag 81
Hartmannella vermiformis 685
 Hatch-Waxman Act 1722, 1765
 Hayflic limit 44
 HBVAXPRO 19
 Health care reform act 1719
 Health products and food branch (HPFB) 1762
 Healthcare
 – costs 1715
 – economics 1762
 – environment 1733
 – payors 1718
 – reform legislation 1718
 Heamin 957
 Heart failure, targeting 1284
 Heat shock proteins
 – levels of expression of different 984
 – synthesis and regulation of cytoplasmic 983
 HEK 293, 156, 744, 775
 HeLa cells 614
Helicobacter pylori 869
Heliotis virescens 483
 Helixate 10, 459
 Helixate FS 459
 Helixate NexGen 10, 459
 Hemagglutinating virus of Japan 236
 Hemangiomas 312
 Hematopoietic agent 466
 Hematopoietic stem cell (HSC) 554
 Hemolysin 383
 Hemo-oxygenase-1(HO-1) 317
 Hemophilia A 10
 – therapy 421
 Hemophilia B 10
 Hemostasis 444
 Hemotaxis 643
 Hemiptera 486
 Hepacare 19
 Heparansulfateproteoglycan 1007
 Heparin 997, 1370
 – binding affinity of rhAT 1005
 Heparin affinity chromatography 1003
 Heparin resistance 1012
 – in CABG patients 1013
 Hepatic metabolic clearance 1796
 Hepatitis B 17
 Hepatitis C 17, 263
 – virus vaccine 1430
 Hepatocyte
 – asialoglycoprotein receptor mediated 1512
 Hepatocyte growth factor, *see* HGF
 HER1 129
 HER2 (human epidermal growth factor receptor 2) 21, 128
 – indicators of 129
 – testing 133
 – testing, algorithm 135
 – /neu oncogene 1277
 HER3 129
 HER4 129

- HERA trial 144
- HerceptTest 77, 134
- Herceptin 22, 64, 77, 128, 455, 479, 526, 1086, 1121
 - adjuvant trials 144
 - antitumor effect 132
 - combination with chemotherapeutic drugs 131
 - development hallmarks 137
 - duration of response 137
 - in early breast cancer 143
 - mechanism, on cellular processes 130
 - monotherapy 138
 - quality of life 137
 - time to progression 137
 - time to treatment failure 137
- Hereditary angioedema 859
- HERG 59
- Hetero duplex analysis 86
- Heterobifunctional inhibitor 403
- Heterochromatin 730
- Heterogeneous nuclear hnRNA 628
- Heterohybridoma CB03
 - chromosome analysis of 770
- Hexadecyltrimethyl ammonium bromide 1493
- Hexavac 19
- Hexosaminidase inhibitor 1047
- HGF (hepatocyte growth factor) 307
- hGH (human growth hormone) 14, 476
 - deficiency 14
- HIF (hypoxia inducible factor) 307
- HighFive 1047
- Highly active antiviral therapy, *see* HAART
- High-performance capillary electrophoresis (HPCE) 1563
- High-performance ion-exchange chromatography (HPIEC) 1562
- High-performance liquid chromatography (HPLC) 84, 1563
- High-performance size exclusion chromatography (HP-SEC) 798, 1562
 - High-resolution computed tomography (HRCT) 1750
- High-throughput cloning 605, 615
- High-throughput screening (HTS) 101, 1606
- Hirschsprung's disease 77
- Hirudin 412
- Hirulog 461
- Hismanal 52
- HIV (human immunodeficiency virus) 263, 1513
 - antiviral gene therapy 554
- HIV-1 (human immunodeficiency virus type 1) 549, 556
 - combinatorial RNA-based therapy 569
 - gag protein 551
 - genes and life cycle of 551
 - pol protein 551
 - provirus 551
 - tat protein 219, 553
 - toxic genes therapy 555
 - vector mobilization 575
 - vectors used in gene therapy 556
- HIV-2 (human immunodeficiency virus type 2) 556
- HKB11 (hybrid of human kidney and B cell)
 - expression platform 1029
- HLA (human leucocyte antigen) 80
- HLA-B57 82
- HMG-CoA 59
- Hoechst epi-fluorescence technique 321
- Holoenzymes 1620
- Homo-arginine 413
- Host cell
 - engineering 732
 - protein 166, 1131
- Host Response Protein Amplification Cascade 1338
- HOST2 220
- HOXB8 223
- HPAEC-PAD (high-performance anion exchange chromatography with pulsed amperometric detection) 800
 - glycan profile of human IgG 801
- HPIEC, *see* high-performance ion-exchange chromatography
- HPLC, *see* high-performance liquid chromatography
- HPSEC, *see* high-performance size-exclusion chromatography
- HuCAL
 - design modularity 1176
 - GOLD antibody library 1159
 - library 1177
- HUM195 506
- Huma ES system 290
- Humalog 12–13, 469, 1456
- Humalog MIX 469
- Human actrapid 470
- Human adenovirus 782
- Human anti-mouse antibody (HAMA) 7, 1109
- Human anti-streptavidin antibody (HASA) 513
- Human antithrombin
 - conformation analysis 1004
 - establishment of transgenic herd 1001
 - glycosylation 1005
 - purification 1003

- Human antithrombin III
 – from transgenic system 855
- Human antithrombin process
 – viral removal or inactivation by 1007
- Human C1 inhibitor
 – from transgenic system 859
- Human cell
 – for organogenesis 353
 – for transplantation 353
- Human chorionic gonadotropin 1326
- Human cytomegalovirus 764
- Human embryonic retina (HER) cell 783
- Human embryonic stem cell (hES) 269, 287
 – derivation of 286
- Human epidermal growth factor receptor 2,
see HER2
- Human fetal mesencephalic cell
 – transplantation of 331
- Human foreskin fibroblast cells (HFF) 637
- Human genome project 230, 622
- Human genome sequencing consortium
 214
- Human germ line structure 771
- Human growth hormone, *see* hGH
- Human immunodeficiency virus, *see* HIV
- Human immunodeficiency virus type 1,
see HIV-1
- Human Insulatard 471
- Human insulin Zn suspension 469–470
 – 30/70 470
 – protamine 471
- Human lactoferrin, expression of, in rice grain
 940
- Human leucocyte antigen, *see* HLA
- Human liver microsomes 1618
- Human lysozyme
 – expression 935
 – recombinant 939
- Human monotard 470
- Human neutral insulin 470
- Human papilloma virus 263
- Human phosphoglycerate kinase (PGK)
 promoter 783
- Human platelet-derived growth factor, *see* PDGF
- Human protein processing 774
- Human retinal pigment epithelial (hRPE) 325
- Human serum albumin (HSA) 275
- Human somatic cell nuclear transfer 273
- Human tissue plasminogen activator
 – from transgenic system 836
- Human umbilical vein endothelial cell (HUVEC)
 1008
- Human velosulin 471
- Human-ether-a go-go-related (hERG) potassium
 channel 1796
- Humaspect 22
- Humate P 459
- Humatrope 14, 476
- Humira 22, 455, 864, 1086, 1112, 1118
- Humulin 12–13, 452, 1449
 – 50/50 469
 – 70/30 469
 – I 469
 – L (Lente) 469
 – M 469
 – M1 469
 – M2 469
 – M3 469
 – M4 469
 – M5 469
 – N 469
 – R 470
 – S 470
 – U 469
 – Zn 469
- Huntington's disease
 – pathways and targets for 625
- Hyaluronic acid 1380
- Hybridoma cells 433
- Hybridomas 820
- Hydrohermatic feed system 160
- 3-Hydroxyacyl-CoA dehydrogenase II 328
- Hydroxycyclophosphamide 131
- N-(Hydroxypropyl)methacrylamide Co-polymer
 1367
- Hydroxysuccinimide ester 1403
- 7-Hydroxy-4-trifluoromethylcoumarin
 (HFC) 1610
- Hygromycin 771
- Hygromycin B 1030
 – phosphotransferase 766
- Hymenoptera 486
- Hyperplasia
 – cytotoxic strategies to reduce neointimal 313
 – gene transfer to reduce neointimal 314
 – neointimal 319
- Hyperuricaemia 24
- Hypoglycemia 14
- Hypoxia 1263
- Hypoxia inducible factor (HIF) 154, 307, 1279
- i**
- IBMX (3-Isobutyl-1-methylxanthine) 292
- Ibraxion 26
- Ibritumomab tiuetan 456, 480
- Ibritumomab tiuxetan 22, 1086

- half life 1168
- in radiotherapy 503
- radio active labeled 501
- IC31 1440
- IC41 1430
- ICH (international conference on harmonisation) 1567
 - guidance for assay validation 1568
 - parties 1680
 - process 1681
- ICH Guidance 1642
- ICH guidelines 434
 - for developed biotech products 1707
- ICH Q5A 1570
- ICH Q5B 1572
- ICH Q5C 1572
- ICH Q5D 1572
- ICH Q5E 1572
- ICH Q6B 1572, 1691
- ICH S6 1692
- ICH S7A 1692
- Identity assay 1566
- Idiopathic pulmonary arterial hypertension, *see* IPAH
- Idiopathic pulmonary fibrosis (IPF) 1750
- Idotamoxifen
 - in breast cancer 524
- Iduronidase alpha 862
- Ifosfamide
 - hydroxylation catalyzed by CYP2B4 1597
- Igef 463
- IgG, light and heavy chains 785
- Igovomab 22
- IHC (immunohistochemistry) 133
- Imagent 1305
- Imiglucerase 475
- Iminase 461
- ImmobaSil carrier 682
- Immukin 467
- Immune response 1425
 - type 1 and 2 1424
- Immune globulin intravenous (IGIV) 1109
- Immuneron 468
- Immunoassays 171
- Immunoblotting 1563
- Immunogenicity 1656
 - of antibodies 1153
- Immunoglobulin 198, 1107
 - subclasses 1424
 - locus 769
 - bivalent 1166
 - post translational modifications 1132
- Immunoglobulin G 862
- Immunohistochemistry (IHC) 116
- Immunoliposomes 1517
- Immunomodulatory molecule 193
 - adjuvants 194
 - DNA-based 195
- Immunomodulation 939
- Immunoscintigraphy with radiolabeled ABS 1123
- Immunostaining 772
- Immunosuppressive drugs 1804
- Immunotoxin, first generation 1125
- Implants 1546
 - drug delivery system 1369
 - polymeric solutions building *in situ* 1374
- IMS (ion mobility spectrometer) 1343, 1345
 - adaptation to MCC-Ni 1347
 - chromatogram examples 1350
 - chromatogram of human exhaled air 1349
 - sources for 1345
 - working principle of 1346
- Imukin 1 467
- Imunace 464, 479
- In situ* hybridisation (ISH) 134
- IND (investigational new drug) 50
 - applications 742
 - submission of pharmacogenetics data to 62
- Indimacis 122 22
- indirect immunofluorescence (IIF) 1190
- indium-111 zevalin 456, 480
- InductOs 24, 464
- Infanrix 18
- Infection, targeting 1285
- Infectious disease era 103
- Inferax 467
- Infergen 17, 467
- Inflammatory bowel disease 1117, 1285
- Inflammatory cytokines 197
- Infliximab 21, 59, 456, 1086, 1118, 1153, 1163
- Influenza virus 484, 1488
- InFuse 464
- Injection, drug delivery system 1369
- Inner cell mass 286
- Inositol-1,4,5-triphosphate 688
- Insect cell culture 1047
 - glycosylation 1047
 - in biopharmaceutical production 1045
 - process cost calculations for 1059
 - protease activities in infected 1049
- Insertions or deletions (InDel) mutations 75
- Inspectional authority for biopharmaceuticals 1653
- Institut für Pflanzengenetik und Naturpflanzenforschung 869

- Institut für Qualität und Wirtschaftlichkeit
im Gesundheitswesen 1721
- Insulatard 13
- Insulatard NPH 471
- Insulin 466, 1376, 1449, 1451, 1465
- analogues 1034
 - biosynthetic, human 1034
 - effect of protease inhibitors on intestinal absorption 1471
 - human 470, 1034
 - industrial scale 1033
 - intestinal absorption using kitosan capsules 1482
 - isophane 469
 - kitosan capsules for delivery of 1480
 - lipophilic index 1473
 - meal 1454
 - native 1474
 - precursor molecule 1036
 - production of 1041
 - structure and its acyl derivatives 1474
- Insulin acyl derivatives
- activity and lipophilic index 1475
 - half lives for proteolysis of 1475
- Insulin aspart 13, 470, 1039
- biphasic 470
- Insulin caproyl derivatives 1476
- transport of 1477
- Insulin degradation
- effect of protease inhibitor on 1469
- Insulin derivatives
- circular dichroic spectra of 1476
- Insulin detemir 13, 470
- Insulin glargine 13, 470
- Insulin glulisine 13, 469
- Insulin injection 1455
- Insulin lispro 12, 469
- biphasic 469
- Insulin precursor expression system 1039
- Insulin-like growth factor type 2 receptor (IGF2R) 218
- Insuman 13, 470
- Insuman basal 469
- Interaction discovery mapping 1325
- Interannular heterobivalent inhibitor 403
- Interannular homobivalent inhibitor 400
- interferon (IFN) 4, 466, 1253
- for *in situ* radiotherapy 510
 - PEGylation 1401, 1404
 - PEGylation by two step approach 1405
- Interferon
- alfa 467
 - alfa-2a 468, 480
 - alfa-2b 468, 480
 - alfacon-1 467
 - alfa-n1 468
 - alfa-n3 467
 - beta 467
 - beta-1a 467
 - beta-ser 467
 - gamma 468, 1750
 - gamma-1a 467, 479
 - gamma-1b 467
 - gamma-n1 468
- Interferon regulatory factor-1 (IRF-1) 233
- Interleukin (IL) 190, 201, 329, 905
- expression system 1022
 - IL-2 465
 - IL4v expression plasmids 1026
 - IL-10 59
- Internal ribosome entry site (IRES) 765
- International biopharmaceutical reference material (IBRM) 1569
- International conference on harmonization, *see* ICH
- International HapMap consortium 77
- Intestine trifol factor (ITF) 942
- expression of, in rice grain 941
- Intron A 17, 468, 480, 1402
- Invader 84
- Investigational medicinal product dossier (IMPD) 1697
- Investigational new drug (IND) 1121, 1638
- application 865
- Invitrogen 1028
- Iodine 499
- Iodoacetamide 1073
- Iododeoxyuridine 1621
- radioactive labeled 519
- Iodogen 1254
- Ion homeostasis 971
- Ion mobility spectra 1348
- Ion mobility spectrometer, *see* IMS
- Ionomycin 272
- Iontophoresis 1382
- IPAH (idiopathic pulmonary arterial hypertension) 1743
- aviptadil treatment 1750
 - causes 1750
- Ipsalazide 1381
- IPW 220
- IRES element 766
- Iressa 76
- Irinotekan 57
- Iron protoporphyrin IX 1582
- Iron-transferrin complex 1426

Ischemia-reperfusion 317
 Isoelectric focusing (IEF) 798
 – capillary 798
 – in purity and homogeneity control 1563
 – profile of purified human IgG from PER.C6 cell 799
 Isoelectric point 1563
 Isophane insulin 469
 Isopropyl-thiogalactopyranoside 1022, 1617
 Itraconazole 55

j

Japan pharmaceutical manufacturers association 1643
 Jervell syndrome 220

k

22k48 220
 K422 526
 Kalikrein 1005
 – inhibition by aprotinin 1027
 Kanamycin 1024
 Kaposy sarcoma 156
 Kaulonemea cell 920
 KCNH2 59
 KCNQ1 59
 Keksin
 – cleavage 1037
 – processing site 1038
 Ketoconazole
 – CYP2C9 inhibitor 1590
 Ketoreductase domain 1810
 Ketosynthase domain 1807
 Kidney
 – allograft transplantation 354
 – xenotransplants 354
 Kidney precursor 359
 – by nuclear transfer 365
 – functionality after transplantation 363
 – *in vitro* propagation 364
 – reduced immunogenicity 362
 Kineret 17, 464, 1118
 Kitosan capsule
 – cross-section of 1481
 – degradation of 1482
 – for insulin delivery 1480
 – gastrointestinal transit of 1481
 – release of carboxyfluorescein of 1482
 Klexane 457
 KLKL5KLK 1434, 1440
 – type 2-inducing adjuvant 1435
 Kogenate 10, 459
 KoGENate 1639
 Kogenate FS 459

Kogenate SF 459
 Kozak sequence 107, 814
 Kringle 5 383
 Kunitz-type inhibitor 1027
 Kupfer cells 1511
 KvLQT1 59
 Kybernin 458, 1004
 Kybernin P 1008
 KyberSept trial 997
 Kyoto encyclopedia of genes and genomes (KEGG) 624

l

Label-free hybridization 87
 Label-free pyrosequencing 87
 LACK antigen 201
 Lactate dehydrogenase 1326
 – Lactoferrin 866
 Lambda recognition recombination reaction 610
 Lambda system 609
 Lange-Nielsen syndrome 220
 Langerhans cell 1429
 Langerhans islet 1033
 Lantus 13, 470
 LARGE 116
 Large degradation clearance 1479
 Large scale biology corporation (LSBC) 861, 864
 Larmor frequency 1215
 Laronidase 475
 Lauryl-maltopyranosidase 1465
 L-CDR1 1177
 L-CDR3 1177
 L-DOPA 325, 332
 – dose 343
 – in Parkinson treatment 330
 – therapy 342
 LEA protein 980
 Lecithin microemulsion, hydrogenated 1550
Legionella pneumophila 685
 Legionellae 685
 Legioner's disease 685
 Leishmaniasis 201
 Lemna 897
 Lentiviral vector 557
 – production of 576
 Lentivirus 551, 574
 Lepirudin 462
 Lernogastim 473
 Leucine enkephalin 1376
 – analog 1473
 Leucomax 472
 Leukemia inhibitory factor (LIF) 288
 Leukemic stem cells 505

- Leukine 6, 16, 472
- Leukoprol 473
- LeukoScan 22
- Leuprolide 1378
- Levemir 8, 12–13, 470
- Levis Y carbohydrate antigen 1172
- Levovist 1305
- Levulinic acid 400
- Lewis molecular model 1623
- Lewis P450 molecular model 1609
- Lewy body 326–327
- Lewy neurite 329
- Lhadi 464
- Ligand 1273
- Ligand-based targeting 1272
- Ligand-binding assay
 - in biopharmaceutical quality control 1563
- Lignan
 - biosynthetic pathway 943
 - expression of, in rice grain 943
- Lilium brownii* 483
- Limit of detection (LOD) 1568
- Limit of quantification (LOQ) 1568
- Limulus amoebocyte* lysate (LAL) 197
 - test 1565
- Limulus polyphemus* 1565
- LINK program 1614
- Linkage disequilibrium (LD) 81
- Linker
 - inter-polypeptide 1812
 - intra-polypeptide 1812
- Linoleic acid 1466
- Lipid
 - film hydration method 1522
 - folate modified 1516
- Lipobay 1604
- LipofectAmine Plus 1526
 - transgene expression 1528
- Lipofectin in gene delivery 1543
- Lipoplex 1526
- Lipoplex 1510
- Lipopolysaccharide (LPS)-mediated inflammatory response 716
- Liposome
 - asialofetuin-labeled 1512
 - cationic 1510
 - complex 1516
 - drug delivery system 1369
 - in nanobiotechnology 1549
 - unilamellae 1370
- 5-Lipoxygenase activating protein (FLAP) 82
- Liposomal gene delivery 1507
- Liposomal parenteral drugs 1370
- Liprolog 12–13, 469
- Liquid chromatography (LC)
 - for peptide mapping 802
- Liquid chromatography/mass spectrophotometry (LC/MS)
 - amino acid determination by 1004
- LIT1 220
- LMAN1 427
- LMW heparin 458
- Locus control region 765
- Long QT syndrome (LQTS) 1605
- Longastatin LAR 478
- Longastatina 478
- 5'-Long-terminal-repeat (5'-LTR) promoter 552
- Loperamide 1795
- Lotronex 52
- Lovastatin 101, 1804
 - metabolized by CYP3A4 1584
- Lovenox 457
- Low molecular mass permeation enhancer 1376
- Lower limit of quantification (LLOQ) 1575
- Lowhepa 457
- Lowmorin 457
- Luciferase 1224
- Luciferin 1224
- Lufa cylindrica* 484
- Lugol's iodine 502
- Lung
 - toxicological effect of nanoparticles 1548
- Lung cancer
 - detection by GC/MS 1344
 - early detection 1343
- Lung tumor
 - PEG-PGA+DON treatment 542
- Luteinizing hormone (LH) 4
- Luteinizing hormone releasing hormone (LHRH) 1361
 - PEGylation 1407
- Lutropin alfa 464
- Luveris 15, 464
- LX1 116
- Lycopersicon cheesmanii* 970
- Lycopersicon esculentum* 970
- Lycopersicon pennellii* 970
- Lycopersicon pimpinellifolium* 970
- Lyme disease vaccine 18
- Lymerix 18
- Lypolex
 - galactosylated 1513
 - mannosylated 1514
- lys224 700
- lys98 698
- Lysergic acid diethylamide 101

- LysoTracker 1499
 Lysozyme 1473
 – antilysozyme antibody 936
 – expression 937
 – expression of human, in rice grain 938
 – recombinant human 936
- m**
- M195 506
 MA 148 539
 mab17-1a 456
 Mabcampath 22, 455, 479
 MabTera 22, 456, 480, 1121
 Macrolin 465, 480
 Macrophages
 – gene transfer to 1513
 – synovial 1284
 Macropinocytosis 1525, 1530
 Macropinosomes 1525
 Macugen 1394
 Mad1 42
 Magainins 486
 Magnetic resonance imaging, *see* MRI
 Magnevist 1217
 MagnICON 902, 909
 Major histocompatibility complex (MHC) 290, 361, 905, 1489
 – MHCII antigen 300
 Major intermediate early (MIE) gene 811
 MALAD-1 220
 MALDI (matrix-assisted laser desorption ionization) 1564
 MALDI-MS (matrix-assisted laser desorption ionization mass spectrometry) 800
 MALDI-TOF (matrix-assisted laser desorption ionization time of flight)
 – traces of glycans of antibody B 800
 – analysis of mPEG MAL-CV-N413 1412
 – galactosylation profile of monoclonal antibodies 801
 – of mosses 925
 MALDI-TOF MS (matrix-assisted laser desorption ionization time of flight mass spectrometry)
 – oligosaccharide profiles determined by 828
 Malein imide 1400
 Maleoyl-alanyl-dipeptide aldehyde 404
Malva parviflora 483
 Mammary adenocarcinoma
 – treatment with GA and DON 543
 Mannitol, overexpression 978
 Mannose 679, 1513
 Mantle cell lymphoma 222
 Manufacturers working cell bank (MWCb) 158, 746
 Manufacturing
 – expression systems for 1093
 – costs 1093
 – strategy 1089
 MAP30 482
 Marker
 – assisted selection 970
 – for angiogenesis 1281
 – in human blood 1326
 – tumor associated 1276
 Market health products directorate (MHPD) 1762
 Marogen 472
 Mass Array 84
 Mass spectrometry (MS) 1564
 – for peptide mapping 802
 – tandem 1564
 Mast cell beta-tryptase 405
 Master cell bank (MCB) 784, 1645
 Master virus bank (MVB) 157
 Master working cell bank (MWCb) 746, 1129
 Mastocytomas 1429
 MAT (malonyl-CoA:ACP transacylase) 1814
 – structure 1815
 Mathay resinol 943
 Matrix metalloproteinase 1227, 1256, 1280
 Matrix-assisted laser desorption ionization, *see* MALDI
 Matrix-assisted laser desorption ionization time of flight, *see* MALDI-TOF
 Matrix-assisted laser desorption ionization time of flight mass spectrometry, *see* MALDI-TOF-MS
 Maximum plasma concentration 51
 Maytansanoids, cytotoxic 1172
 MCFD2 427
 MDR1 58
 Meal insulin 1454
 Measles-mumps-rubella vaccine 1421
 Mecasermin 465
 Medical and scientific advisory council (MASAC) 424
 Mef2b 294
 Mef2c 290, 294
 MEK1 257
 MEK2 257
 MEKK1
 – phosphorylation inhibition of 1746
 Mellaril 64
 Memapsin 1782
 Membrane lipids
 – levels of 989

- MEN1 220
- 2-Mercaptoethanol 1070
- 6-Mercaptopurine 64
- Meristem 990
- Mesenchymal stem cell (MSC) 285, 366
- Messenger RNA, *see* mRNA
- Metabolism prediction
 - computational approaches 1609
 - *in vitro* techniques 1613
- 1-Metaiodobenzylguanidine 499
- Metalyse 11, 462
- Metastatic colon cancer 206
- Methanethiosulfonate 1400
- Methioninesulfoximine (MSX) 735, 766
- Methionyl-tRNA transformylase 1068
- Methotrexate (MTX) 76, 131, 734, 766, 1030
- N-Methyl-aspartate (NMDA) 638
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 327–328
- Metoprolol 61
- Methylenetetrahydrofolate reductase (MTHFR) 76
- Metrodin HP 464
- Metronidazole
 - CYP2C9 inhibitor 1590
- Mettox
 - assay 1603, 1608
 - molecular model 1623
- Metypone 1588
- Mevacor 1730
- MF59 1425
- Miacalcic 477
- Miacalcic NS 477
- Mibefradil 52
- Micro array analysis
 - of gene silencing 258
- Micro RNA, *see* miRNA
- Microbial pathogenesis
 - *D. discoideum* as model for 685
- Microbubbles 1282, 1310, 1318
 - conjugates 1311
 - for ultrasound imaging 1219
 - targeting 1319
- Microcapsules
 - preparation with a double emulsion technique 1373
- Microcarrier 739
- Microciona prolifera* 485
- Microcystis viridis* 484
- Micro-electrode array mapping technique 292
- Micro-gene-gun 1318
 - non-invasive 1544
- Microinjection, pronuclear 1000
- Microneedle 1541
 - system 1383
- Microspheres
 - biodegradable 1487
 - hydrophobic 1371
 - drug distribution in 1372
 - for encapsulated DNA vaccines 1492
 - hydrophilic 1374
 - immunoresponses 1500
 - polyorthoesters for 1496
 - uptake by macrophages 1499
 - using polyesters 1493
- Midazolam
 - metabolized by CYP3A4 1585
- MIDGE vector (minimalistic immunogenetically defined gene expression) 183
 - application of 198
 - characteristics 189
 - immunization pathways using 200
 - immunomodulating 191
 - production 188
 - smart 191
 - structures 187
- Milyzer 461
- Mimic Sf-9 cell 1047
- Mimotope 1194
- Minidaltol 457
- Ministry of health, labour and welfare (WHLW) 1643
- MIRD schema 523
- Mirimostim 473
- miRNA (Micro RNA) 222, 628
- Mistral 458
- Mitogen activated protein kinase 1 (MAPK1) 258
- Mixtard 13
- Mobenakin 464, 480
- MOG (myelin oligodendrocyte glycoprotein) 1193
- 8-18C5 epitope on 1204
 - (8-18C5)-fab complex 1201
 - antibody responses against 1199
 - structure of 1201
- Molecular dynamics 1609
- Molecular imaging 1309
 - applications 1235
 - contrast agents for 1225
 - for drug discovery 1230
 - modality properties 1229
- Molecular rational design
 - of product development 703
- Molgramostim 472

- Moloney murine leukemia virus (MoMLV) 574
 Momordica charantia 484
 mondoBIOTECH 1741, 1749
 Monoaminoxidase B 330
 Monoclate 459
 Monoclate-P 459
 Monoclonal antibody (MAb) 20, 1105
 – analytical methods for 1116
 – application areas of 1116
 – approved therapeutics 1120
 – by perfusion technology 743
 – CIPP strategy 1128
 – cytotoxic drugs and toxins linked to 1124
 – expression systems 1135
 – fed-batch and perfusion cultivation 1087
 – generation 1109
 – generic manufacturing strategy 1129
 – glycosylation of 1135
 – heavy and light-chain polypeptides 906
 – huNR-LU-10 862
 – immunogenicity 1657
 – manufacturing 1083, 1126
 – market demands 1714
 – market perspectives 1119
 – physical properties of 1128
 – release specifications for 1130
 – routine manufacture 1127
 – therapeutic 1086
 Monophospholipid A 194
 Monotard 13, 470
 Monteplase 461
 Moroctocog-a 10
 Moss
 – cell culture 922
 – glycoengineering in 927
 – in biopharmaceutical production 920
 – transformation 921
 Mouse antibody production test (MAP) 434
 Mouse, chimeric 657
 Mouse embryonic fibroblast 286
 Mouse, gene targeted 649
 Mouse lymphage assay 1624
 Mouse minute virus (MMV) 434
 Mouse, transgenic 1111, 1162
 6-MP 57
 MRI (magnetic resonance imaging) 346, 1215
 – application 1217
 – macrophage imaging 1282
 – paramagnetic agents 1217
 – prion disease imaging 1289
 – schematic set-up 1216
 – supermagnetic agents 1217
 mRNA (messenger RNA) 628
 MSCB (master seed cell bank) 746
 MTHFR, *see* methylenetetrahydrofolate reductase
 MTT (3,4,5-cimethylthiazol-2yl-2,5-diphenyl tetrazolium bromide) 640
 Mucolytic enzymes 1376
 Mucopolysaccharidosis 24, 862
 Multiangle light scattering (MALS) 162
 Multilamellae vesicles 1370
 Multifunctional-type nanodevice (MEND) 1522
 – transfection activities 1524
 Multilase 461
 Multiple sclerosis (MS) 17
 – epidemiology 326
 Multiplexing strategy 87
 Multiplicity of infection (MOI) 1048
 – determination of high or low 1049
 Multi-wavelength anomalous dispersion 1066
 Murine embryoid body 289
 Muromomab 1086
 Muromomab-CD3 456
 Murray breast tumor 131
 Mutagenesis 592, 666
 – change-of-specificity 1818
 – combinatorial cassette 706
 – loss- and gain-of-function 1817
 – novel polyketides by change-of-specificity 1820
 – random oligonucleotide 706
 Mutual recognition agreement (MRA) 1677
 MVL 484
 MWCBs *see* manufacturers working cell bank
 MWCBs *see* master cell bank
 Myasthenia gravis 1188
 Mycobacterium tuberculosis 1422
 Myelin basic protein 1200
 Myelin oligodendrocyte glycoprotein, *see* MOG
 Mylotarg 22, 454–455, 480, 1086, 1121, 1125, 1172
 Myoblasts 320
 Myocardial infarction 11
 – imaging by NIR 1284
 Myocardial regeneration
 – strategies 295
 – using hES 283
 Myocyte enhancer factor 294
 Myomap 1305
 MyoSzint 21
 Myxococcus xanthus 1824

n
 Nadroparin calcium 457
 NAF 483
 Nanocrystal technology 1538

- Nanocrystals
 - Quantum dot 1539, 1545
- Nanofact 459
- Nanoparticles 1306
 - solid lipid 1373
- Nanospheres, hydrophilic 1374
- 2-Naphthylalanine 413
- Nartogastrim 473
- Nateplase 461
- National center of biotechnology information (NCBI) 254
- National institute of health (NIH) 1233
- Natrecor 476
- N-cadherin 320
- NCE 1685
- NCRMS 220
- NCSU-23 275
- Near infrared (NIR) principle 1222
- Nelfinavir 58
- Neo 299
- Neo gene 665
- Neocarcinostatin chromophore 1125
- Neocolipor 25
- Neocormon 16
- Neokidney 369
- Neomycin 299
- Neomycin phosphotransferase 766, 897
- Neoplastic disease
 - antibody treatment for 1121
- Neorecormon 472
- Nesiritide 476
- Nespo 8, 16, 472
- Neulasta 16, 473, 1406, 1730
- Neumega 4, 17, 464
- Neupogen 16, 473, 1406, 1755
- Neupopeg 16, 473
- Neurokinin antagonist
 - identified by Pep2Lead approach 1781
- Neurokinin receptor agonist 1780
- Neurokinin receptor antagonist 1779
- Neuronal cell line NCA1 775
- Neuron-specific enolase 1326
- Neutrogen 473
- Neutrophil 1195
- Neu-Up 473
- New biological entities 1362
- New drug application (NDA) 50, 1638
 - submission of pharmacogenetic data to 62
- NiaStase 459
- Nicotiana benthamiana*
 - GNTI from 902, 925
- Nicotiana tabaccum* 950
- Nicotine 58
- Nicotinic acetylcholine receptor 1188
- Nifedipine
 - metabolized by CYP3A4 1585
- NIH3T3 156
- Niphatevirin 485
- Nitric oxide synthase (NOS) 316
 - endothelial 316
 - inducible 316
- p-Nitrophenyl phosphate 714
- Nkx2.5 290
- NMR, *see* Nuclear magnetic resonance
- Non-Hodgkin lymphoma 21
 - antibody treatment 1121
 - clinical trials of RIT 501
 - radioimmunotherapy 500
- Non-protein-coding RNA, *see* npcRNA
- Nonproteolytic activator 388
- Nonsmall cell lung cancer 222
- Noratak 476
- Noravid 461
- Norditropin 14
- Norditropin Nordiflex 477
- Norditropin SimpleXx 477
- Normiflo 458
- Northern blot analysis of ITF levels 942
- Nostoc elyosporum* 483, 1406
- Novact M 459
- Novetumomab 21
- Novolin L 470
- Novolin N 471
- Novolin R 470
- Novolog 13, 470
- Novolog 70/30 FlexPen 470
- Novolog FlexPen 470
- Novolon 13
- NovoMix 30 13, 470
- NovoMix 70 470
- NovoRapid 13, 470
 - 30Mix 470
- Novos 464
- NovoSeven 10, 459
- npcRNA (Non-protein-coding RNA)
 - linked to human disorders 220
- NS0 728, 763
- NSCLC 220
- Nuclear factor kappa B 317
- Nuclear imaging 1220
- Nuclear magnetic resonance (NMR) 1066
- Nuclear polyhedrosis virus (NPV) 27
- Nuclear translocation 1530
- Nutropin 14, 477
- Nutropin AQ 477
- Nutropin Depot 477

O

- OATP-C 58
- OCC1 220
- Octreotide 1376
- Oct-4 276
- Octin 464, 480
- Octreoscan 519, 1226
- Octreotide 478
- ODN *see* oligonucleotide/oligodeoxynucleotide
- Office of new drug chemistry (ONDC) 1639
- Office of new drugs (OND) 1639
- Office of regulatory affairs (ORA) 1639
- Office of therapeutics research and review (OTRR) 1639
- Official control authority batch release (OCABR) 1680
- Official medicines control laboratories (OMCL) 1680
- OGamma100 468
- Oidragit R 1381
- Oidragit RL 1381
- Oidragit RS 1381
- Oif 467
- OKT3 101
- Oldenlandia affinis* 484
- Oligodeoxynucleotide (ODN)
 - antisense 230, 313–314
 - CG-motifs 195
 - c-myc antisense 316
 - containing CpG motifs 1437
 - decoy 314
 - double-stranded decoy 230
 - inhibition of phospholamban 318
 - mechanism of action 231
 - PT-based 198
 - single stranded phosphodiester based 196
- Oligofectamine 573
- Oligonucleotide (ODN)
 - chimeric 1533
 - mediated polymorphism recombination 590
 - P-labeled 526
 - single stranded 1533
 - triplex forming 525, 1533
- Oligonucleotide ligation assay (OLA) 84
- Olsalazine 1381
- Omalizumab 456, 1086
- Omeprazole 61
- Oncaspar 475, 480, 543, 1399, 1411
- Oncogenes 732
- OncoLAR 478
- Oncology
 - imaging 1249
 - radiolabeled drugs for 1250
 - therapeutics 1249
- OncoSzynt 21
- Oncovirus 551
- Ononitol, overexpression 978
- Ontak 7, 24, 456, 480
- Onzar 456, 480
- Oocyte
 - *in vitro* culture 274–275
- OP-1 464
 - implant 464
- Open reading frame, *see* ORF
- OP/LMWH 457
- Oprelvekin 464
- Optical imaging 1222
 - applications 1223
 - contrast agents for 1223
- Optisulin 13, 470
- Oral application
 - use of nanoparticles for 1549
- Oral hypoglycemic agents 1459
- Oral spray insulin
 - in diabetes type 2 treatment 1455
- Oralin 1445
 - administration 1451
 - as meal insulin 1454
 - chronic administration 1458
 - delivery 1446
 - dose-response relationship 1452
 - efficacy 1457
 - mechanism of absorption 1448
 - properties 1448
 - radiolabeled 1450
- Oralin RapidMist delivery device 1447
- ORF (open reading frame) 170, 248, 605, 610, 1045
- Orgasuline rapide 471
- ORMUCS 1787
- Orthoclone 21, 456
- Orthoclone OKT3 454, 456, 1086
- Oryctes rhinoceros* 486
- Osmolytes levels 988
- Osteogenic protein 24
- Osteoporosis 15
- Osteotonina 477
- Ovalbumine 234
- OVCAR3 539
- Overall dyskinesia rating scale 339
- Overall glycemic control 1457
- Ovidrel (Ovitrelle) 477
- Ovitrel 15
- Oxalis tuberosa* 483

Oxazaphosphorine
 – hydroxylation catalyzed by CYP2B4 1597
 4-Oxo-butiric acid 400
 Oxygen uptake rate 825
 Ozogamicin 455

p

p123 39
 p43 39
Pachymatisma ionstonii 482
 Pachymatismin 482
 Paclitaxel 101, 131, 137, 139, 314, 1367
 – for *in situ* radiotherapy 510
 – in cancer treatment 1172
 – metabolized by CYP2C8 1594
 PAGE (polyacrylamide gel electrophoresis)
 – kinetics of thrombin activation 437
 Paget's disease 15
Palicourea condensata 484
 Palicourein 484
 1-Palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) 1508–1509
 Palivizumab 21, 456, 1086
 – against infectious disease 1176
 Pallidotomy 331
 Pamiteplase 462
 PAMPA (parallel artificial membrane permeation assay) 1787
 Panax ginseng 482
 Panorex 456
 Parallel line analysis (PLA) 168
 Paraquat 328
 Parathyroid hormone 1378
 Paratope 1190
 Parkin gene 329
 Parkinson disease (PD) 77, 325
 – epidemiology 326
 – pathways and targets for 625
 – therapy 329
 Parnaparin sodium 457
 Paroxetine 61
 Parvovirus MVM 747
 Pathogen-associated molecular pattern (PAMP) 194
 Pathogen viruses
 – infection risk attenuation in fVIII concentrates 423
 Patients' responsibility 1737
 Pattern track process 1334–1335
 Paxton ovarian tumor 131
 pBR322 156
 PCGEM1 220
 PCNA (proliferating cell nuclear antigen) 316
 PCR (polymerase chain reaction) 134, 607
 – application of B-type DNA polymerase 709
 – performance in 712
 – product identity test by 167
 – transgenic animal cell analysis 1000
 – quantitative 1564
 PDGF (platelet-derived growth factor) 153
 Peak cell density 1052
 PEBBLES technology 1546
 PECAM-1 360
 Pediarix 19
 PEG, *see* poly(ethylene)
 Pegademase bovine 475
 Pegaspartase 475, 480
 Pegasys 17, 468, 1402, 1411
 – properties of 1403
 Pegfilgrastim 16, 473, 1406
 Peginterferon alfa-2a 468
 Peginterferon alfa-2b 468
 PEGIntron 468, 1401–1402
 – properties of 1403
 Peguptanib sodium 1394
 Pegvisomant 478, 1404, 1411
Penicillium nalgiovense 483
 Pep2Lead 1772
 – concept 1778
 PepHarvester algorithm 1779
 Peptic agent 474
 Peptide
 – active sequence 1779
 – antimicrobial 1286, 1433
 – aptamers 638
 – design system 1779
 – directed radiotherapy 516
 – effect of protease inhibitors on 1470
 – FITC-tat 637
 – in disease targeting 1275
 – intestinal absorption 1463
 – leader 1037
 – mapping 802, 1195, 1562
 – nasal delivery of 1378
 – phage libraries 1275
 – PEGylation of 1407
 – radiotracer 1256
 – spacer 1038
 – stability 1469
 – transporter 636–637
 – ubiquicidin-derived 1286
 – vaccination 1429
 Peptide biopharmaceuticals
 – chemical modification 1472
 Peptide, cationic
 – delivery system 1419, 1437

- vaccine adjuvants 1426
- Peptide, cationic antimicrobial 1419
- artificial 1433
- as vaccine adjuvant 1433
- subgroups 1433
- Peptidoglycan 938
- PER.C6 724, 764, 775
- human cell line 779
- PER.C6 cell 728
- characterization of antibodies by 797
- fed-batch process development 789
- for manufacture of recombinant protein 784
- generation of 782
- transfection 785
- PER.C6 cell line
- batch process profiles 791
- continuous perfusion process 794
- growth data for antibody producing 790
- supplemented batch process 793
- PER.C6 clones
- generation of, for monoclonal antibody 784
- Percutaneous transluminal intervention (PTI) 313
- Percutaneous transluminal coronary angioplasty (PTCA) 236
- Perfusion scintigraphy 1238
- Peripheral blood mononuclear cell (PBMC) 361
- Peripheral blood progenitor cell (PBPC) 1757
- Permeation clearance 1480
- Peroxidase stress inducible 894
- Personalized medicine 76
- Pertussis 18
- Pertuzumab 1164
- PET (positron emission tomography) 499, 1220, 1243
- cancer therapy by 1243
- for Alzheimer targeting 1286
- imaging of cancer 1243
- monitoring of radiolabeled drugs 1252
- radioisotopes for 1244
- radiopharmaceuticals for 1246
- radiotracer 1246
- PET (positron emission tomography) imaging
- of apoptosis 1262
- of end-points of tumor 1259
- of gene expression 1255
- of glucose metabolism 1260
- PEVKEK region 1199
- PGA (pseudomonas 7A glutaminase-asparaginase) 539
- antitumor effect of 539
- efficacy of 539
- PHACIR (pharmacophore identification routine) 1771, 1778, 1781
- concept 1776
- Phage artificial chromosome (PAC) 656
- Phage display technology 1112
- Phagocytes 1548
- Pharmaceutical research and manufacturers of America (PhRMA) 1643
- Pharmaceutically Tractable Genome (PTG) 99
- Pharmacodynamics
- PET studies 1254
- Pharmacogenetics 49
- environmental factors and 75
- terms 74
- Pharmacogenetics research network (PGRN) 77
- Pharmacogenomics 49
- environmental factors and 75
- terms 74
- Pharmacokinetics
- intracellular 1526, 1529
- in quality control of biopharmaceuticals 1576
- of biopharmaceuticals 1253, 1365
- of gene delivery systems 1254
- of PEG 1396
- of small molecules 1250
- Pharmacophore concept 1776
- Pharmacophore identification routine, *see* PHACIR
- PharmaCos DG Enterprise 1676
- Pharmazymes 1613
- Phenylpropanoid metabolism 943
- Phenytoin
- metabolized by CYP2C9 1590
- Phosphato-dihydrofusidate 1376
- Phosphinothricin acetyltransferase 898
- Phosphoenol pyruvate 1075
- Phosphoethanolamine N-methyltransferase 978
- Phospholamban 318
- Phospholipids 1376
- PHS Act 1640
- Physcomitrella patens* 905, 919
- GNTI from 925
- PHYSPROP database 1789
- Pichia pastoris* 713, 1135
- Picornia virus 766
- PINK1 gene 329
- Pinocytosis 1397
- Pinoresinol 943
- Pip (pristinamycin-induced proteine) 732
- pIVEX (plasmid for *in vitro* expression) vector 1066
- PIVI-Argonaute-Zwille domain (PAZ) 246
- pJM17 156

- PLA (process licence application) 742
- Plasminogen, mini 380
- Plant
- genetically modified 894
 - production of recombinant proteins in 893
 - production of stress tolerant 974
 - water balance 971
- Plant cell
- effect of additives on product yields 957
 - for biopharmaceutical production 949
 - responses to stresses 972
- Plant cell suspension cultures
- recombinant proteins from 951
- Plant derived biopharmaceuticals
- N-glycosylation 924
- Plant plasma membrane
- K inward rectifying channel 973
 - K outward rectifying channel 973
 - voltage independent cation channel 973
- Plant, transgenic, *see* transgenic plants
- Plasma insulin concentration 1482
- Plasmacytoma 763
- Plasmid DNA 1532
- based vector 186
 - methods for quantifying subcellular distribution 1527
 - purification 1068
 - templates for wheat embryo system 1067
- Plasmid stability
- of IL4v expression vector 1026
- Plasmid-encoded selection gene (POD) 1035
- Plasmin 1005
- inhibition by aprotinin 1027
- Plasminogen 461
- Plasminogen
- activation 380
 - activator 1074
 - micro 380
- Plasmodium falciparum* 1422
- Plasmodium falciparum* circumsporozoite protein (CSP) 682
- Plasvata 461
- Platelet-derived growth factor, *see* PDGF
- Pleomycin 666
- Pleurotus ostreatus* 482
- Polio 18
- virus 263, 766
- Polyadenine
- in gene delivery 1543
- Polyarginine 1425
- as type I-inducing adjuvant 1429
 - CpG-ODN-based vaccines 1439
 - stimulatory efficacy on T cells 1431
 - vaccine adjuvant 1426
 - with CpG-ODN 1437
- Polybutylcyanoacrylate 1310
- Polycyanoacrylate 1305
- Polydimensional SNP 88
- microarray 89
 - platform 88
- Polydimethylsiloxane, nonbiodegradable 1546
- Polyesters
- for DNA vaccine delivery 1492
- Poly(ethylene glycol) (PEG) 957, 1076
- acylating reagents 1398
 - conjugates with 1367, 1393
 - properties 1394
 - reagents 1397
 - reagents for protein PEGylation 1398
 - pharmacokinetic parameters 1396
- PEG8/IGF2AS 220
- PEG-adenosinedeaminase 1411
- PEG-asparaginase 1411
- PEG-biphalin 1410
- preformulation 1410
- PEG-conjugates, analysis of 1411
- PEG-CV-N-conjugates, molecular weight analysis of 1413
- PEG MAL-CV-N reverse-phase purification 1414
- PEG-staphylokinase, preformulation 1409
- Polyethyleneimine 1316
- in gene delivery 1543
- Polyferon 468
- Poly(glutamic acid) 1368
- Poly(glycolic acid) 1494
- Polyglycolide 1305
- Polyhistidine
- in gene delivery 1543
- Polyketide 1804
- biosynthetic gene cluster 1806
 - heterologous hosts for production of 1824
 - key reactions of biosynthesis 1809
 - natural products engineering 1803
- Polyketide synthase 1804
- biosynthesis 1806–1807
 - classification of 1806
 - engineering of novel polyketides 1815, 1820
 - organization of 1808
 - precursor-directed biosynthesis 1819
 - production requirements 1822
 - tailoring steps in erythromycin synthesis 1811
 - structure of natural products 1805
- Poly(lactic acid) 1491, 1495
- Poly(lactic-co-glycolic acid) 1492
- Poly lactide 1305

- Poly(lactide-co-glycolide), for peptide encapsulating 1371
- Polylysine 1316, 1512
 - mannosylated 1514
 - vaccine adjuvant 1426
- Polymer
 - bulk erosion 1491
 - design for DNA vaccine 1493
 - hydrolysis 1491
 - synthetic, biodegradable 1491
- Polymer conjugates
 - commercially available 1368
- Polymer erosion rate 1495
- Polymer nanoparticles, two-step process 1306
- Polymerase
 - II 217
 - III 217
 - Pfu 709
 - Taq 709
 - Tgo 709
- Polymerase, b-type
 - structural features 710
- Polymerase chain reaction, *see* PCR
- Polymeric microsphere 1371
- Polymeric permeation enhancer 1376
- Polymeric solution 1374
- Polymyositis-scleroderma overlap syndrome 1193
- Poly(orthoester)
 - cytotoxicity 1499
 - feed composition and characterisation of 1496
 - for DNA vaccine delivery 1494
 - microspheres 1487
 - synthesis 1494
- Polyoxyethylene 400
- Polyoxyethylene-20-stearyl ether 1376
- Polyoxyethylene-24-cholesterol ether 1376
- Polypeptide synthase
 - typical structure of 1816
- Poly(styrene-maleic acid anhydride) 1367
- Polyvinylpyrrolidone 957
- Pompe disease treatment 861
- Pondimin 52, 1604
- Pooling strategy 87
- POPC, *see* 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine
- Population genetics 81
- Porcilis AR-T DF 25
- Porcilis pesti* 26
- Porcilis porcoli* 25
- Porcine biphasic insulin 471
- Porcine embryo 275
- Porcine endogenous retrovirus (PERV) 369
- Porcine fetal mesencephalic cell
 - transplantation of 332
- Porcine isophane insulin 471
- Porcine neutral insulin 471
- Porcine pseudorabies virus (PRV) 434
- Pork atrapid 471
- Pork insulatard 471
- Pork mixtard 30, 471
- Portfolio assessment 1735
- Posicor 52
- Positive transcription elongation factor 219
- Positron emission tomography, *see* PET
- Postcommisural putamen 343
- Post-glutamyl peptide hydrolysis (PGPH) 398
- Post-prandial glucose 1456
- Poststreptococcal glomerulonephritis (PSGN) 384
- Post-transcriptional gene silencing (PTGS) 571
- POT1 (protection of telomeres protein) 43
- Prader-Willi syndrome (PWS)
 - pathways and targets for 626
- Pravastatin 58
- Prediction error sum of squares 1796
- Pregnane X receptor (PXR) 1788
- Prescription behavior 1736
- PREVENT 237
- PREVENT-I trial 315
- Prexelizumab 1116
- Primavax 19
- Prion 746
 - disease targeting 1287
- Pristinamycin-induced protein (Pip) 732
- Pro inflammatory cytokines 1511
- Processing procedure
 - downstream 5
 - upstream 3
- Prociclide 461
- Procomvax 19
- Procrit 3, 16, 472
- Product patents 1758
- Progesterone
 - CYP3A4 activated 1587
 - metabolized by CYP2C3 1595
- Prokine 472
- Prolastin 464, 858
- Prolastina 464
- ProLease-rhGH 477
- Proleukin 17, 465, 480
- Proliferating cell nuclear antigen, *see* PCNA
- Proline 974
 - catabolism 974
 - dehydrogenase 974

- uptake 1435
- Pro-opiomelanocortin (POMC) 1327
- Propion aldehyde 1399
- Propulsid 52, 1605
- Proquest system 614
- Prostacycline 1007
- ProstaScint 21, 744, 1277
- Prostate cancer
 - PGA and DON treatment 540
- Prostate-specific membrane antigen (PSMA) 1277
- Prostatic acid phosphatase 1326
- Protamine 1531
- Protaphane 13
- Protease
 - baculovirus encoded 1049
- Protease inhibitor 395, 1467
 - absorption-enhancing mechanism 1472
 - effect on insulin degradation 1469
- Protein kinase A (PKA) 318
- Protein
 - anti-apoptosis 821
 - anti-bacterial 485
 - anti-cancer 481
 - anti-fungal 482
 - anti-viral 483
 - as disease marker 1337
 - based agents 460
 - Bcl-2 family of 819
 - biopharmaceuticals 1463
 - body 935
 - chemical modification 1472
 - disulfide bonded 1072
 - drug sources 481
 - endogenous 938
 - heat shock 982
 - human 774
 - identification 1337
 - intestinal absorption 1463
 - levels 988–989
 - marker 1327
 - milk expression technology 998
 - nasal delivery of 1378
 - optimized BEVS-based 1048
 - production in plants 893
 - ribosome-inactivating 482
 - selenium-cysteine labeled 1066
 - selenium-methionine labeled 1066
 - storage 938
 - synthesis and secretion in cultured plant cells 957
 - transduction 636
 - transgenic derived 870
- Protein-1, activated 236
- Protein A, immobilized 1130
- Proteinase 3
 - peptide mapping of epitopes on 1195
- Protein C
 - activated 457
 - concentrate 457
- ProteinChip array
 - antibody-coupled 1337
 - types of 1329
- ProteinChip reader
 - sample analysis in 1330
- ProteinChip system 1325
 - applications 1334
- Protein data bank 380
- Protein disulfide isomerase 1074
- Protein diversity
 - generation of 586
- Protein expression 934
 - examples 682, 1094
 - for recombinant protein deposition 935
 - using ExpressTec in grains 945
 - using transitional machineries 936
- Protein-fragment
 - complementation assay 1161
- Protein G 1130
- Protein kinase
 - for drug development 639
- Protein L 1130
- Protein production
 - baculovirus based 1050
 - cell free 1064
 - generic protocol 1050
 - infection kinetics 1052
 - nutritional/kinetic parameters in baculovirus based 1051
 - protocol for BEVS-based 1057
- Protein, recombinant, *see* recombinant protein
- Protein screening
 - high content 594
 - high-throughput 594, 596
 - spectroscopic methods 595
- Protein stability
 - factors affecting 956
- Protein storage vacuole 935
- Protein therapeutic dendrogram 113
 - Protein therapeutics (PT) 104
- Protein toxin
 - conjugates 1173
 - linked to MAb 1124
- Protein transduction domain peptides 1523
- Proteolysis
 - intravascular 380

- pericellular 380
 - Proteomics 30
 - Protexia 870
 - Prothrombin 380
 - activation 379
 - Protropin 14, 477
 - Pro-urokinase 462
 - Prous Integrity database 453
 - Pseudomonas* 7A glutaminase-asparaginase, *see* PGA
 - Pseudomonas aeruginosa* 686, 1010
 - infection 1751
 - Pseudomonas* exotoxin A 1173
 - Pseudomonas syringae* 483
 - PsorBan 637
 - Psoriasis 1285
 - pSP65 vector 1067
 - PSZA11q14 220
 - Pulmonary arterial hypertension (PAH) 1742, 1749
 - Pulmonary vascular resistance (PVR) 1749
 - Pulmozyme 23, 475
 - Pure System 1068
 - cell free from *E. coli* 1069
 - Puregon 15, 465
 - Puregon Pen 465
 - Purinethol 64
 - Purity
 - analytical methods for determination of 1567
 - Puromycin N-acetyl-transferase 766
 - Putrescein 1075
 - Pyrimidine nucleoside radiolabeled 1262
 - Pyrococcus furiosus* 709
 - Pyrogen test 1565
 - Pyroline-5-carboxylate 975
 - Pyrosequencing 87
 - Pyrrhocoricin 486
 - Pyruvate dehydrogenase 1075
 - Pyruvate-formate lyase 1075
- q**
- Q6B 1692
 - Qiagen kit 90
 - QS21 1424
 - QSAR equation 1787
 - QT genes 59
 - Quality control
 - analytics in 1557
 - international guidelines 1571
 - Quantison 1305
 - Quantitative structure-activity relationship 1611
 - Quantitative structure-property relationship 1791
 - Quantitative trade loci 969–970
 - Quixidar 454, 457
- r**
- RACHITT 590
 - Radioimmunoassay (RIA) 1563
 - Radioimmunoconjugates 508
 - Radioimmunotherapy (RIT) 498, 1125
 - pre-targeted 512
 - therapeutic index 511
 - Radioisotope
 - positron emitting 1244
 - Radiolabeling
 - monitored with PET 1251
 - of anti-cancer drugs 1251
 - iododeoxyuridine 519
 - of pyrimidine nucleoside 1262
 - Radionuclides
 - for targeted *in situ* radiotherapy 499
 - Radiopharmaceuticals 1246
 - Radiosynthetic methods 1246
 - Radiotherapy 497
 - biopharmaceuticals for 497
 - HuM195 dose 506
 - ibritumomab tiuxetan dose 504
 - *in situ* 497
 - M195 dose 506
 - maximum tolerated dose 502
 - tositumomab dose 503
 - Radiotracer 1253
 - antibodies for 1258
 - peptides for 1258
 - properties 1248
 - small molecule 1256
 - RAEL 526
 - rAHF-PFM 459
 - Raji B-cell lymphoma 526
 - RANTES 363
 - Rap1 43
 - Rap1p 42–43
 - Rapacuronium bromide 52
 - Rapamune 1538
 - Rapamycin 101, 314–315, 1804, 1818
 - Raphanus sativus* 483
 - Rapid amplification of cDNA ends (RACE) 109
 - RapidMist
 - accuracy of dose delivery 1449
 - device 1449
 - Rapilysin 11, 462
 - Raplon 52
 - Raptiva 454, 456, 1086
 - Rasburicase 475
 - Rat antibody production test (RAP) 434

- Raxar 52
 RAY1/ST7 220
 Rayleigh scattering 1305
 RB69-polymerase 710
 RCR (recombination chain reaction)
 – homologous recombination by 591
 R&D portfolio 1733
 Reactant ion peak 1347
 Rebetrone 17
 Rebif 17, 467, 1404
 RecDNA somatotropin 477
 Receptor tyrosine kinase (RTK) 639
 RECIST criteria 1259
 Recombinant Antihemophilic Factor VIII 424
 Recombinant blood factor 9
 Recombinant factor VIII (rFVII) 420, 459
 Recombinant HB 1422
 Recombinant hematopoietic growth factor 15
 Recombinant hepatitis B surface antigen
 (rHBsAg) 3
 Recombinant hormone 14
 Recombinant human vascular endothelial
 growth factor, *see* rhVEGF
 Recombinant IFN 16
 Recombinant IL 16
 Recombinant insulin 12
 Recombinant protein 189
 – companies using plant based 904
 – expressed in cultured plant cells 952
 – from nuclear transgenes 895
 – in cereal grains 932
 – in plastids 898
 – plant made, commercially available 903
 – PER.C6 cell for 784
 – post translational modifications of 955
 – production 672, 907, 1726
 – transient expression levels 901
 – vectors for 730
 Recombinant thrombolytics 11
 Recombinate 10, 421, 459
 Recombinate rAHF 1639
 Recombination chain reaction, *see* RCR
 Recombivax 18
 Recombivax HB 1639
 Recormon 472
 RECTSER 76
 Redux 52, 1604
 ReFacto 10, 459
 ReFacto AF 459
 Reference sequence 255
 – database 110
 Reference standards
 – for analytical testing 1569
 Recludan 23, 462
 REGENT-I trial 316
 Regranex 24, 465
 Regulations
 – EU-US comparability guidelines 1693
 – for biological products 1686
 – for biopharmaceuticals 1641, 1682
 – for cell lines 1645
 – for dosage forms 1646
 – for drug product 1647
 – for drug substance 1648
 – for formulation components 1646
 – for manufacturing process 1647
 – for purification phase 1646
 Regulatory bodies 1676
 REM sleep disorder 328
 Remicade 21, 456, 864, 1086, 1118–1119
 Renal cell carcinoma 17
 Renal cell replacement
 – strategies for 368
 Renal toxicity
 – from PDRT of malignancies 517
 ReoPro 462, 1086, 1117
 Reovirus type 3 (REOV-3) 434
 Repaglinide 58
 Repeat induced point mutation 244
 Replagal 23, 475
 Replication competent adenovirus (RCA) 166
 Reporter gene assay, non-invasive 1228
 Reporter genes 671
 Residual DNA 167
 Respiratory syncytial virus (RSV) 263, 454
 Respitin 463
 Re-stenosis 235
 – arterial 313
 Restriction endonucleases 168
 Restriction enzyme-mediated integration
 (REMI) 667
 Restriction fragment length polymorphism
 (RFLP) 84
 Retavase 11, 462
 Reteplase 11, 462
 Reticulo endothelial system 1366
 – in DNA vaccine delivery 1490
 Retinal pigment epithelial cell, *see* RPE
 Retinoic acid 294
 Retrovirus 31, 551, 574
 RETTAU 77
 Revasc 23, 462
 Reverse phase high-performance liquid
 chromatography, *see* RP-HPLC
 Reverse transcriptase polymerase chain reaction
 (RT-PCR) 290

- Reversible perfusion defect size (RPDS) 177
 - Reviparin sodium 457
 - Rev protein 552
 - Rev response element (RRE)
 - Rezulin 52
 - r9a 699
 - R-Ferone 467
 - Rhabdomyosarcoma 222
 - RheoPro 21
 - Rheumatoid arthritis 17, 24, 79
 - pathways and targets for 626, 1284
 - RhinoRx 866
 - rhVEGF (recombinant human vascular endothelial growth factor)
 - moss derived 923
 - Ribavirin 17
 - Ribonucleic acid, *see* RNA
 - Ribosomal binding site 1023
 - Ribosomal RNA, *see* rRNA
 - Ribosome display 1112
 - Ribozymes 570
 - Rice endosperm, expression of lignan 944
 - fusion strategy to express small peptide in 942
 - Ricinus communis* 1173
 - Rif1 43
 - Rif1p 43
 - Rif2p 43
 - Risperidone 101
 - Rituxan 21, 456, 480, 503, 526, 1086
 - application 1278
 - Rituximab 21, 456, 480, 503, 526, 1086, 1164
 - cell killing trigger 1169
 - RNA (ribonucleic acid) 628
 - *see also* under special RNA types
 - -based therapy for HIV 569
 - micro- 216
 - steroid receptor activator 218
 - transfer- 215
 - ribosomal- 215, 628
 - RNAi (RNA interference) 31, 244
 - diversity of viral targets 571
 - expression of vector-based approaches for 631
 - in treatment of viral infection 262
 - mechanism 245
 - pathway 629
 - silencing 571
 - silencing genes as tools and therapeutics 624
 - therapeutic applications 259, 570
 - RNA-induced silencing complex (RISC) 571, 629
 - RNase inhibitors 1079
 - Roceron-A 468, 480
 - Roferon 1411
 - Roferon A 17, 468, 480
 - Roller bottle
 - optimum MOI, TOI and TOH in 1053
 - process 737
 - Romano-Ward syndrome 220
 - Rosiglitazone clearance 1594
 - Rosuvastatin
 - label recommendations 55
 - Rotenone 327–328
 - Rous sarcoma
 - retrovirus 764
 - virus 263
 - RPE (retinal pigment epithelial cell)
 - human 333
 - location and anatomy of 335
 - microcarrier bound 338
 - PD treatment of 336
 - RP-HPLC (reverse-phase high-performance liquid chromatography) 164, 436, 1562
 - rRNA (ribosomal RNA) 628
 - Rs-AFP2 483
 - RTQ-PCR 116
 - RU-41740 463
 - Rush dyskinesia scale 340
 - Russel-Silver syndrome 220
 - Rybozyme 634
- S**
- Saccharomyces cerevisiae* 399, 1021, 1033, 1422, 1628, 1824
 - expression platform 1027
 - expression vector 1035
 - Saccharopolyspora erythraea* 1804
 - Sacrophaga peregrine* 1434
 - Safety working party (SWP) 1670
 - Saizen 14, 477
 - Salmon calcitonin 477
 - Salmonella typhimurium* 1011, 1625
 - Sandoparin 454, 458
 - Sandostatin 478
 - Sandostatin LAR 478
 - Sanitation era 103
 - Sapecin B 1434
 - Saponaria officinalis* 484
 - Sargramostim 472
 - Satin/APOE system 78
 - SCA8 220
 - Schizophrenia
 - pathways and targets for 627
 - Schizosaccharomyces pombe* 571
 - TPI1 gene from 1035
 - SciTropin 476

- Scleroderma autoantigen centromer protein 1191
 SCN5A 59
 SCNT (somatic cell nuclear transfer)
 – embryo 279
 – oocytes 272
 Scopolamine 1382
 Scytovirin 484
 SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) 725, 1563
 – antibody detection 1077
 – of human IgG produced in PER.C6 cells 798
 – of total soluble protein from rice grain 940
 – of total soluble protein from transfected *Nicotiana* leaves 909
 – PEG-conjugate analysis 1411
 Secoisolariciresinol 943
 beta-Secretase 1782
 – enzyme assay 1784
 – virtual screening 1784
 Seldane 52
 SELDI (surface-enhanced laser desorption ionization) process 1335
 – distinctions of 1333
 SELDI TOF-MS (surface-enhanced laser desorption ionization time-of-flight mass spectrometry) 1325
 Selective combinatorial randomization (SCR) 592
 Selectively infective phages 1112
 Seleparina 457
 SELEX technique 635
 Self-organizing maps 1797
 SEM micrograph of microcapsules 1373
 Sendai virus liposome 235
 Sensitive particle acoustic quantification 1308
 – procedure 1313
 Sepsis 24
 Sequencing
 – by hybridization 84
 – for structure determination 1562
 Sequential random mutagenesis 705
 SERCA2a 318
 Serine protease inhibitor 1005
 Serine proteinase
 – activation mechanism 390
 – cascades 379
 – mechanism 377
 – trypsin-like 378
 Sermorelin acetate 476
 Seroson follicle-stimulating hormone 9
 Serostim 14
 Serotim 477
 Serum amyloid A 1337
 Serum amyloid protein 1287
 Serzone 1604
 Severe combined immunodeficiency (SCID) 361
 SHARP 218
 Shepheridin 1 486
 Shepheridin 2 486
 Shikimate-chorismate pathway 943
 Short tandem repeat 277
 shRNA (short hairpin RNA) 243, 247, 573
 Shuttle vector 156
 Sical 477
 siD direct 255
 siFect system 632
 Signalling pathways, and their disease implication 625
 Silicon, in drug delivery 1540
 Silteplase 461
 Simian immunodeficiency virus (SIV) 556
 Similar Biological Medicinal Products Legislation (SBMPL) 1764
 Simulect 21, 456, 1086
 Simvastatin 58
 Single nucleotide polymorphism, *see* SNP
 Single photon emission computed tomography, *see* SPECT
 SIP1 42
 SIRAN 681
 siRNA (small interfering RNA) 573
 – biopharmaceutical drugs 632
 – characteristics 630
 – chemical synthesis 631
 – delivery of 632
 – design parameters 248
 – individual 257
 – interaction with RISC 249
 – *in vitro* transcription of 631
 – mechanism of action 630
 – off-target effects 256
 – peptide based 573
 Sirolimus 314
 Sjörgen syndrome 1190
 Skeletal myoblast 285
 Small cell lung cancer 21
 Small fragment homologous replacement method 1533
 Small interfering RNA, *see* siRNA
 Small molecule therapeutic target (SMT) 104
 Small nucleolar RNA, *see* snoRNA
 Small nucleolar RNP, *see* snoRNP
 Small organic molecules, in disease targeting 1275
 Small pox 1488

- Small temporal RNA, *see* stRNA
- Small-vessel vasculitis 1195
- Smith-Watermann, dynamic programming
 - sequence alignment algorithm 255
- SMP-140 477
- Snakin proteins 485
- SNaPshot 84
- Snell law 1218
- snoRNA (small nucleolar RNA) 215, 628–629
- snoRNP (small nucleolar RNP) 41
- SNP (single nucleotide polymorphism) 71
 - analysis 85
 - scan 77
 - technology 83–84
- SNP-IT 84
- Sodium 5-methoxysalicylate 1465
- Sodium caprate 1376
- Sodium deoxycholate 1465
- Sodium dodecyl sulfate-polyacrylamide
 - gel electrophoresis, *see* SDS-PAGE
- Sodium glycocholate 1465
- Sodium glycodeoxycholate 1376
- Sodium salicylate 1376, 1466
- Sodium taurodihydrofusidate 1376
- Softenon 1675
- Solanum lycopersicum 970
- Solanum tuberosum 485
- Solclot 462
- Solid tumor 1174
 - RIT of 507–508
- Solinase 462
- Soluble insulin 471
- Somatic cell nuclear transfer, *see* SCNT
- Somatomedin-1 463
- Somatonorm 477
- Somatostatin receptor
 - in peptide directed radiotherapy 516
- Somatotropin 477
- Somatrem 477
- Somatropin 476–477
 - recombinant 477
- Somavert 15, 478, 1404, 1411
- Somazon 465
- Sonavist 1305
- Sonoporation 1318, 1382
- SonoVue 1305
- Sorangium cellulosum* 1804
- SOS stress response 1627
- SOS-umuC assay 1627
 - industrial validation studies 1633
- Sotalol hydrochloride 1605
- Sotocor 1605
- Southern blot 83, 134, 654
 - transgenic animal cell 1000
 - of IgG expressing PER.C6 clones 786
- Southern hybridization
 - of genomic DNA 736
- Soybean trypsin inhibitor 1470, 1472
- SPECT (single photon emission computed tomography) 177, 261, 1220
 - applications 1222
 - contrast agents for 1222
 - for Alzheimer targeting 1286
 - principles and instrumentation 1220
 - spatial resolution 1221
- Spermidine 1075
- Spheramine 325
 - dosing 344
 - microcarrier 336
 - treatment 344
- Sphingosine kinase-1 (SPHK-1) 218
- Spinal muscle dystrophy (SMA) 78
- Spin-lattice relaxation time 1216
- Spin-spin relaxation time 1215
- Spiramycin 1818
- Spodoptera frugiperda* 1047
- Squamous cell carcinoma 238
- SRA-Del 220
- SSCP 84
- SSEA-1 276
- SSEA-3 276
- SSEA-4 276
- Sso polymerase 711
- Staphylocoagulase, prethrombin-2 complex 387
- Staphylocoagulase SC 386
- Staphylococcus aureus* 1129, 1350
- Staphylokinase, plasminogen complex 384
- Staphylokinase (SAK) 381, 383
- STAT-1 233
- STAT-3 233
- Stem cell, myocardial regeneration, using 320
 - neural 332
- Sterilize in place (SIP) 746
- Stimulated acoustic emission 1308
 - principle of 1309
- Stiripentol
 - CYP2C9 inhibitor 1590
- Stop codon suppression 667, 670
- Strattera 56, 64
- Streptavidin 511
 - coupling to microcapsules 1310
- Streptococcus mutans* 865
- Streptococcus pneumoniae* 1421
- Streptococcus pyogenes* 1130, 1422
- Streptokinase, plasminogen complex 385
- Streptokinase (SK) 381, 384

- Streptomyces avidinii* 511
Streptomyces coelicolor 1823
Streptomyces lividans 1824
Streptomyces peucetius 1804
 Stromal antigen 1281
 stRNA (small temporal RNA) 628
 StSN1 485
 StSN2 485
 Substrate recognition site 1584
 SUBSTRUCT
 – analysis 1794
 – classification of CNS activity 1795
 – classification with 1792
 – fragmentation scheme of propanol 1793
 Succinimidyl carbonate 1398
 Succinimidyl propionate 1398
 Succinimidyl succinate 1398
 Succinylcholine 74
 Sucrose acetateisobutyrate 1374
 SUDHL-1 515
 Sulesomab 22
 Sulfaphenazole derivative
 – co-complex with CYP2C5 1596
 Sulfasalazine 1381
 Sulfhydryl redox potential 1073
Sulfolobus solfataricus 711
 Sulfglycotide 463
 Sulfurhexafluoride 1305
 Suniferon MP 468
 Supermagnetic iron oxide, ultra small 1218
 Superoxide dismutase
 – ROS scavengers 979
 Superparamagnetic iron oxide 1218
 Supersomes 1613, 1618
 Surface-enhanced laser desorption ionization,
 see SELDI
 Surface-enhanced laser desorption ionization
 time-of-flight mass spectrometry, see SELDI
 TOF-MS 1325
 Surface-enhanced Neat Desorption (SEND) 1337
 Surgical therapy in Parkinson treatment 331
 Survival motor neuron (SNM) gene 78
 SV40 764
 SW620 116
 S-warfarin
 – CYP2C9 complex 1591
 – forms of 1593
 – metabolism 1592
 – therapeutic effect 1591
 Swiss biotech BOUTIQUE 1741
 SwissPro database 170
 Sybyl 1610
 Synagis 21, 454, 456, 1086, 1121, 1176
 Synthetic oviductal fluid
 – modified with amino acids 269, 274
 Synuclein alpha 329
- t**
 T cell
 – activation 1501
 – adjuvant 1431
 – lymphoma 24
 Tac 20
Tachyplesus tridentatus 1565
 Tacrolimus 58
 Tagging gene disruption (knock-in) 670
 Taillefer selectivity 1283
 Tamoxifen 61
 – metabolized by CYP3A4 1584
 Tandem MS QSTAR 1335
 Tanimoto index 1777
 TAP 29 484
 TaqMan 84
 TAR RNA decoys 231
 Tarceva 143, 1122
 Tasonermin 463, 479
 Taste blindness 74
 TATA box 764
 Taurodeoxycholate 1376
 Taxanes 140, 1252
 Taxol 314, 835
 Taxotere 101
Taxus cuspidata 950
 TAXUS trial 315
 Taz1 43
 TBlastN algorithm 108
 TBP 764
 Tecleukin 464, 479
 Tecnemab KI 22
 Telomerase 38
 – human 42
 – reaction cycle 40
 – regulation of 42
 – RNA functions 41
 Telomerase reverse transcriptase (TERT) 39
 Telomere
 – alternative lengthening of 44
 – protection 43
 Temozolomide 1251
 – radiolabeled 1253
 Tenascin 509
 Tenecteplase 11, 462
 Tepase 461
 Teratoma cells 299
 Terfenadine 52, 1788
 Terfenamide 1795

- Teriparatide 476
- Terminal deoxynucleotide transferase dUTP nick and labeling 644
- Testosterone 58, 1589
 - hydroxylation 1618
- Tetanus 18
- Tetracycline (TET) 732, 896
 - system 632
 - use 1804
- 12-O-Tetradecanoylphorbol-13-acetate 223
- Tetragastrin 1473, 1477
 - permeability 1479
 - structure 1478
- Tetragastrin acyl derivatives 1478
 - acid-output time curves 1479
- Tetrahymena enzyme 38
- Tetrahymena thermophila* 685
- Tev-Tropin 476
- Texas Red 1427
- TGGE 84
- Therapeutic angiogenesis 153
 - human clinical trials for 309
- Therapeutic cloning 269
- Therapeutic drug monitoring 1574
- Thermococcus gorgonarius* 709
- Thermoplasma acidophilum* 399
- Thermus aquaticus* 709
- Thienylalanine 413
- Thioepa 131
- Thioflavin T 1287
- Thiomedazine 64
- 4-Thio-oligoribonucleotide 261
- Thiopurine methyltransferase (TPMT) 57
- Thioredoxin reductase 1073
- Thrombate III 454, 458, 855, 1004
- Thrombin 380
 - heterobivalent inhibition 411
 - imaging 1283
 - inhibition assay 1006
- Thrombin-antithrombin (TAT) complex 997
- Thrombin inhibitor 1778
 - design of 1780
- Thrombolyse 462
- Thrombosis, targeting 1282
- Thrombospondin th-1 (TSP1) 263
- Thymalfasin 478
- Thymidine 1261
 - action of radiolabeled 1263
- Thymoglobuline 456
- Thyrogen 14
- Thyroid cancer 14
- Thyroid stimulating hormone (TSH) receptor 1189
- Thyrotropin- α 14
- Thyrotropin-releasing hormone 1473
- TILLING 990
- Time of harvest (TOH) 1053
- Time point of infection (TOI) 1048
- TIN2 43
- Tisokinase 461
- Tissue inhibitor of metalloproteinase (TIMP) 811, 813
- Tissue plasminogen activator (tPA) 6, 1280
 - human 836
 - recombinant 746
- TNF, *see* tumor necrosis factor
- TNKase 11, 462, 744
- Tobacco cultivars Bright Yellow 2 950
 - suspension cells 951
- Tobacco mosaic virus (TMV) 864
 - vectors 900
- Tolbutamide, metabolized by CYP2C9 1590
- Toll-like receptor (TLR)
 - in DNA vaccine 1490
- Tomieze 462
- Tonocalcin 477
- TOPAS algorithm 1774
- TOPKAT 1624
- TOPO 611
- Toramide
 - metabolized by CYP2C9 1590
- Tositumomab 104, 455, 479, 1086
 - half life 1168
 - in radiotherapy 502
 - radio active labeled 501
- Total soluble protein 933
 - from rice grain 940
- Toxicity
 - complement directed 1156
- Toxins, bacterial 1125
- TRA-1-60 276, 288
- TRA-1-81 276, 288
- TRAFFIC trial 307
- TRAIL 264
- Transannular heterobivalent inhibitor 399
- Transcription activator protein 1428
- Transcription gene silencing (TGS) 571
- Transdermal therapeutic system 1382
- Transfectants
 - selection conditions 815
- Transfection 727
- Transfer RNA, *see* tRNA
- Transferin receptor 1517
- Transferins 1517
- Transfersomes 1382
- Transforming (tumor) growth factor (TGF) 294

- Transgene 156
- Transgene combining ability (TCA) 990
- Transgene expression 1531
- Transgenic animals 29
 - biopharmaceuticals from 833, 995
- Transgenic derived biopharmaceuticals
 - oral vaccines from 867
 - trials as anti-infective agents 865
- Transgenic derived pharmaceuticals
 - trials for autoimmune treatment 862
 - trials for cancer treatment 862
- Transgenic mice 1111, 1162
- Transgenic plants 29
 - biopharmaceuticals from 833
 - draught and salt tolerance 969
 - expressing genes involved in ion transporter 974
 - expressing genes involved in osmolyte biosynthesis 976
 - expressing genes involved in redox reactions 979
 - high temperature stress 981
 - production of high temperature stress tolerant 985
 - production of high temperature tolerant 984
 - stress tolerance 967
- Transgenic system
 - and post translational modifications 849
 - capacity of production 846
 - costs 847
 - production strategies and materials used for extraction 837
 - regulatory experience 850
 - therapeutic proteins derived from 852
 - therapeutic use 857
- Transillumination 1223
- Transmembrane semaforines 104
- Transmissible spongiform encephalopathy (TSE) 1007
- Trastuzimab 479
- Trastuzumab 22, 64, 455, 1086, 1164
- Trasylol 854
- Trehalose synthesis 978
- Treponema pallidum* 1422
- Tresylate 1400
- TRF1 43
- TRF2 43
- Triacelluvax 19
- Trichloroacetic acid 1077
- Trichosantes chirilovii* 484
- Trichosanthin 482, 484
- 2,5-bis(Trifluoromethyl)-7-benzoyloxy-4-trifluoromethylcoumarine (BFBFC) 1610
- Tripartite protein 1166
- Tritanrix-HB 18
- tRNA (transfer RNA) 628
 - amber suppressor 674
- TRNG10 220
- Troglitazone 52
 - clearance of 1594
- Troparin 457
- Trophectoderm 275
- Trovert 478
- Trudexa 22, 455
- Trypanosoma brucei* 571
- Trypsin 1005
 - alpha-antitrypsin 463
 - inhibition by aprotinin 1027
 - from transgenic system 853, 858
- Tryptase, alfa 405
 - diketopiperazine-based biphasic inhibitor 412
 - inhibition by cyclodextrin-based inhibitor 408
 - inhibition by PEG-linked inhibitor 406
- Tryptofan fluorescence assay 1006
- TrypZean 854, 903
- Tuberculosis 1489
- Tubulin polymerization inhibitor 1172
- Tumor angiogenesis 1278
- Tumor associated antigen (TAA) 183
- Tumor-associated glycoprotein 72, 1276
- Tumor cell, targeting markers on 1276
- Tumor growth index 523
- Tumor hypoxia, assessment of 1263
- Tumor necrosis factor (TNF) 7, 80, 264, 481
- Tumor therapy 537
 - cell based 203
 - DNA based 202
 - peptide based 205
- Tumor volume doubling time 1321
- Tunnel assay 644
- Turbocalcin spray 476
- Turner's syndrome 14
- Twinrix 19
- tyr177 699
- tyr99 697
- Tyrosinase 1429
- u**
- UBE3A 277
- UBE3A-AS 220
- UBI (ubiquicidin-derived)-peptides 1286
- UCOE/UCOS (ubiquitous chromatin opening element) 730, 765
- UGT1A1 57
- UK national health service 1719

- UK national institute for clinical excellence (NICE) 1720
- Ultrafiltration 159
- Ultra-high-throughput screening (uHTS) 596
- Ultrasonic spectroscopy
 - microcapsule formulations 1307
- Ultrasound
 - theranostics 1301
 - 3-D imaging 1304
- Ultrasound contrast
 - encapsulated gas bubbles 1305
- Ultrasound contrast agent
 - diagnostic and therapeutic use 1315
 - for gene delivery 1318
 - preparation of drug-loaded 1317
 - properties 1308
 - target-specific 1314
- Ultrasound device
 - loss of correlation 1308
 - stimulated acoustic emission 1308
- Ultrasound imaging
 - application 1218
 - microbubbles as contrast agents 1219
 - schematic set-up 1220
- Ultratard 13
- Umatrope 476
- Umuline zinc 469
- Unified PD rating scale (UPDRS) 337
- UniGene 255
- United Kingdom centre doctors' organization (UKHCDO) 424
- United Kingdom prospective diabetes study (UKPDS) 1446
- United network for organ sharing (UNOS) 354
- United States department of agriculture (USDA) 897
 - voluntary scrapy flock certification program 1007
- United States federal laws for biopharmaceuticals 1640
- United States federal register 1641
- United States national hemophilia foundation (NHF) 424
- United States prescription drug marketing act 1736
- Urbason 1314
- Urofollitropin 464
- Urokinase 380
 - -plasminogen activator 1280
- Ussing chamber method 1479
- V**
- Vaccination
 - immune response 1421
 - targets for therapeutic 1422
- Vaccine 18
 - adjuvants 1419, 1425
 - cellular 1429
 - combination 1421
 - DNA based 199
 - responder rate 1432
 - transgenic derived oral 867
 - viral 1421
- Vaccinia topoisomerase 611
- Valgis 1675
- Validation characteristics
 - dependent on application 1569
- Valproic acid 687
- Vascular cell adhesion molecule-1 (VCAM-1) 234
- Vascular proliferative disease 235
- Vascular re-endothelialization 319
- Vascular smooth muscle cell (VSMC) 313
- Vasoactive intestinal peptide (VIP)
 - human 1742
 - molecular mechanism and transcription 1745
 - structure 1744
- Vector
 - blastid based 897
 - for expression of recombinant proteins 730
 - for gene therapy 186
 - for production of recombinant proteins in plants 894
 - for transient transformation 900
 - non viral 1522
 - polycistronic 730
 - systemic viral 901
- Vector design
 - AIDS therapy 559
- VEGF (vascular endothelial growth factor) 263, 307
 - as disease marker 1337
 - productivity of mass bioreactor for 905
- Veldona 467
- Velosulin 13
- Velosulin BR 471
- Venn diagram 111
- Venous thrombosis 23
- Verapamil clearance 1594
- Verluma 21
- Veterinary biopharmaceuticals 25
- Vibragen 26
- Vinorelbine 131
- Vinplastine 131
- Viola arvensis* 484
- Viraferon 17, 468, 480

ViraferonPeg 468
 Viral vector generation 156
 Virosomes 1425
 Virtron 17, 468
 Virus based vector 186
 Virus purification 158
 Virus safety 1650
 Visceral endoderm 294
Viscum album 482
 Visudine 1280
 VitoTox 1628
 Vitravene 24, 633
 Vivid screening kit 1613
 VNTR (variable number of tandem repeats)
 marker 77
 Volatile organic compounds 1344
 Von Hippel-Lindau disease, pathways and targets
 for 628
Vorvariella volvacea 482
 Votumumab 22
 VPAC1 receptor 1745
 VPAC2 receptor 1745
 VSMC (vascular smooth muscle cell) 313

W

WalkThrough recombination 706
 – alkaline phosphatase with 712
 – evolution of cIAP 713
 WalkThrough technique
 – for optimizing diagnostic proteins 707
 Warfarine 57
 Watson-Crick base-pairing 38
 Wave bioreactor 1050
 – fed-batch conditions 1053
 – oxygen mass transfer coefficients 1055
 – oxygen transfer for insect cell culture in
 1055
 – scale up 1053
 Wegener granulomatosis 1195
 Wellferon 468
 West Nile virus vaccine 779
 Western blot 1563
 – analysis of alpha-glucosidase 861
 – of rhAT 1001
 – of transgenic rice grains carrying ITF
 gene 943
 Wheat embryo
 – cell free expression of biopharmaceuticals
 using 1063
 Wheat embryo extract
 – composition of media and buffer 1071
 Wheat embryo system
 – plasmid DNA templates 1067

 – translation under reducing/oxidizing condi-
 tions 1078
 Willebrand factor 425, 1153
 Wilm's tumor 221, 359
 (With-no-lysine) kinase-4 (WNK4) 78
 Wnt-binding proteine 294
 Wolffian duct 355
 Working Cell Bank (WCB) 1645
 World Drug Index (WDI) 1790
 World Health Organization (WHO) 1569

X

Xanelim 456
Xenopus laevis 486, 1228
 Xenotropic leukemia virus (X-MuLV) 434
 Xigris 4, 24, 465
 X-inactive specific transcript 217
 Xolair 454, 456, 1086
 X-ray computed tomography (CT) 1213
 – resolution 1214
 X-ray technique 1213
 – contrast agents for 1214
 Xylose 849
 2-Xylosyltransferase 925

Y

Yaspin 1 1036
 Yeast 20S proteasome 398
 – inhibition by heterobivalent inhibitors 400
 – inhibition of PGPH and trypsin activities 404
 – inhibition by monovalent inhibitors 401
 Yeast agglutinin 1161
 Yeast artificial chromosome 1111
 Yeast cell surface display 1112
 Yeast expression vector 1028
 Yeast-2-hybrid system 1161
 Yeast signal trap 109
 Yttrium-90 Zevalin 456, 480
 Yttrium-DOTALAN 518
 Yttrium-DOTATATE 518
 Yttrium-DOTATOC 516

Z

Zadaxin 478
 Zeemann effect 1215
 Zemaira 464
 Zenapax 21, 456, 1086
 Zevalin 22, 454, 456, 480, 501–502, 1086, 1121,
 1169, 1234
 – application 1278
 Zocor 1730
 Zoladex 478
 Zomacton 476

Zona pellucida 276
Zopiclone clearance 1594
Zorbtive 477
Zot 1376
Zovant 465

Zymogen 381
– activator 388
– form of fIX 697
Zystic fibrosis 23